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 General Abstract 
Schizophrenia is a chronic enduring disorder ranked among the most debilitating mental illnesses 
(Mueser & McGurk, 2004; Tandon, Keshavan, & Nasrallah, 2008). Although it has been vigorously 
studied over the past century, the etiology and pathophysiology of schizophrenia remains largely 
unknown and currently available treatments, in the form of antipsychotics, are mainly unsatisfactory 
(Insel, 2010; Tandon et al., 2008). 
Schizophrenia is characterized by three broad types of symptoms: positive symptoms, negative 
symptoms, and cognitive deficits. While drugs currently available for the treatment of this disorder 
are effective for positive symptoms, negative symptoms (including social impairments) and cognitive 
deficits still remain mainly untreatable.(Keefe et al., 2007; Neill et al., 2010). Negative and cognitive 
symptoms are more pervasive, fluctuate less over time than psychotic symptoms and are strongly 
associated with poor psychosocial functioning in community living and work (Kasper & Resinger, 
2003; Mueser & McGurk, 2004; Tandon, Nasrallah, & Keshavan, 2009). 
Although there have been rapid progress in the development of non-invasive technologies to study 
human brain structure and function in the last two decades, there are still substantial limitations in 
our ability to investigate details of the physiology and molecular biology of the human brain (Nestler 
& Hyman, 2010a). To that end, it is imperative to have carefully validated animal models for 
continued progress in our understanding of pathophysiology and in the development and screening of 
novel therapeutic agents in order to enhance functional recovery of patients (Davis et al., 2013; Neill 
et al., 2010).  
Neuropeptides have an important role in intracerebral signaling and might have the potential to be 
used as therapeutic agents in many psychiatric and neurological diseases(Bedse, Di Domenico, 
Serviddio, & Cassano, 2015; Erbaş, Çınar, Solmaz, Çavuşoğlu, & Ateş, 2015; Nishimura, Murayama, & 
Takahashi, 2015; Reglodi et al., 2015, 2015). Unfortunately, they usually can’t be administered 
systemically due to the elevated hydrophilicity and molecular weight that prevent them to overcame 
the blood brain barrier. 
Intranasal administration might be a promising and non-invasive way of administration of 
neuropeptides: this administration route enables highly hydrophilic and high molecular weight 
molecules to bypass the blood-brain barrier permitting them to reach the brain in a non-invasive way. 
This way has been demonstrated in in humans that permits the delivery of biologically effective 
concentrations of many peptides to the brain without eliciting significantly eventual systemic 
hormone-like side effects (Born et al., 2002); This route of administration was tested also in mice and 
rats (Born et al., 2002; Neumann, Maloumby, Beiderbeck, Lukas, & Landgraf, 2013)and, recently, was 
successfully used specifically in the context of behavioural studies in in mice (Huang et al., 2014). 
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The aim of the studies described in this thesis is to investigate, through the use of clinically-relevant 
animal models of schizophrenia, the pharmacogenetics behavioral effects of intranasal administration 
of two different neuropeptides: 
- oxytocin (OXT), a neurohypophyseal peptide suggested to have beneficial effects in social 
behaviors (Meyer-Lindenberg, Domes, Kirsch, & Heinrichs, 2011; Striepens, Kendrick, Maier, & 
Hurlemann, 2011) and currently in clinical studies for mental disorders characterized by social 
behavioral alterations such as autism (Anagnostou et al., 2012; Guastella et al., 2010) and 
schizophrenia (Feifel et al., 2010).  
- CRF(6-33), a syntetic peptide designed to be an effective competitive antagonist for the 
binding between the endogenous CRF neuropeptide and its binding protein (CRFbp)(Sutton et 
al., 1995) suggested in preclinical ICV studies to be an effective pro cognitive agent with 
potential therapeutic applications (Stephen C. Heinrichs & Joppa, 2001; Stephen C. Heinrichs, 
2003; Koob & Bloom, 1985)  
 
In previous work from our laboratory (Huang et al., 2014), we already implemented, for the first time, 
the use of intranasal oxytocin in C57BL/6J mice, checking different behavioral effects. Thus, we now 
tested the effects of intransal OXT in the schizophrenia-relevant dysbindin-1 knockout mouse model. 
Genetic variations of the dysbindin-1 gene (DTNBP 1) has been associated with susceptibility to 
schizophrenia (O’Tuathaigh et al., 2007; Ross, Margolis, Reading, Pletnikov, & Coyle, 2006; Straub et 
al., 2002) and severity of negative symptoms and cognitive dysfunction in schizophrenic patients 
(Burdick et al., 2007; DeRosse et al., 2006; Fanous et al., 2005; Straub et al., 2002). Thereafter, using a 
Dys knockout mutant mouse model, we demonstrated that both the heterozygous and homozygous 
knockout mice manifested a reduction in social interaction compared to wildtype mice. Similar social 
deficits in Dys mutant mice have been reported by other groups (Feng et al., 2008; Hattori et al., 
2008).  
Interestingly, both chronic and acute intranasal OXT treatments were able to ameliorate the social 
deficits observed in the Dys knockout mice. These data suggest that intranasal oxytocin might be 
beneficial to subjects with genetic modifications relevant to schizophrenia, while administration to 
healthy subjects has not significant behavioral effect or may eventually be detrimental (Huang et al., 
2014).  
This opens new ways of exploration in relationship to the beneficial effects of OXT treatment and its 
utility in the clinical setting.  
The data (aforementioned) correlate well with the molecular data available. As a matter of fact, OXT 
receptors are downregulated in WT subjects that are chronically IN –OXT treated, and even mutant 
mice, though treated with the same therapeutic protocol, show that the receptors are not subject to 
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variation , compared to the control subjects treated with the vehicle substance only. Indeed, after 
being chronically treated, WT mice showed a decrease in social behaviour, while mutant mice (under 
an equivalent OXT treatment) showed an increase in social behaviour. 
For the CRF(6-33) part, in order to set the ground for future studies with genetically modified mice, 
disease-related mouse models and facilitate inter-laboratory comparisons, we first tested the effects 
of both chronic and acute intranasal CRF treatments in C57BL/6J mice. Considered that OXT did not 
show significant improvement in cognitive performance, we chose to target these functions with a 
different peptide that in previous intracerebroventricular studies had shown to improve cognitive 
functions (Behan et al., 1995; Eckart et al., 1999; S C Heinrichs et al., 1997; Stephen C Heinrichs & 
Koob, 2004; Stephen C. Heinrichs & Joppa, 2001; Stephen C. Heinrichs, 2003; Koob & Bloom, 1985; 
Lee, Lee, Wang, & Lin, 1993; Lee & Sung, 1989; Thompson, Erickson, Schulkin, & Rosen, 2004) had 
shown to improve cognitive functions . To asses cognitive functions we used a modified version of the 
5-Choice Serial Reaction Time Task (5-csrtt), a rodent test designed as analog of the Continuous 
Performance Test (cpt) used to asses quantitatively attentional control in humans (Amitai & Markou, 
2011). The modifications are intended to reduce the time needed to train the animals , reduce 
stressful manipulations as food restriction or single housing. Additionally, several new manipulations 
have been implemented to investigate various specific cognitive functions such as attention, broad 
monitoring / compulsivity, response disinhibition/ impulsivity, distractibility and processing speed. 
 
 We were able to demonstrate that the intranasal administration of CRF(6-33) can produce selective 
behavioral effects in mice. In particular, acute administration was able to improve accuracy of 
responses and reduce impulsivity, while chronic administrations produced a delay in correct 
responses. Gene expression studies with real time PCR are starting to suggest that the CRF(6-33) is 
able to reach the brain, as both CRFr1 and CRFbp were altered following intranasal CRF(6-33) in 
different and specific brain areas (i.e. Hippocampus and Prefrontal Cortex ). 
Subsequent dose-response tests confirmed the ability of evocate behavioral effects with a much 
lower dose of CRF(6-33). Moreover, we discovered a rebound effect in impulsive behavior the day 
after administration of higher doses.. This detrimental effect was absent with the lowest doses that 
was still able to significantly reduce impulsive behavior. 
Lastly we tested ability of CRF(6-33) to ameliorate an impulsive phenotype in a genetic modified 
mouse model of schizophrenia. The chosen model was a double mutant for Dysbindin and for the 
receptor D2. The D2 receptor that had proven in previous test to have an increased impulsive 
behaviour.  
The dopamine D2 receptor (D2) gene is another important risk gene identified for schizophrenia. 
Functional genetic variants in the D2 gene have been found to be differently expressed in patients 
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with schizophrenia (Kaalund et al., 2013) and might modulate schizophrenia-related phenotypes by 
modifying the ratio of the short isoform (D2S) to the long isoform (D2L) (Bertolino et al., 2009). 
Heterozigote mutant for D2L has an increased D2S (receptor D2 short form)/ D2L (receptor D2 long 
form) ratio.  
From preliminary data CRF(6-33) was not able to significantly affect impulsive behaviour in double 
heterozygote Dys +/- D2L +/- . Interestigly, in single heterozygote Dys +/- was observed a trend of 
increased impulsivity il CRF(6-33) group suggesting a detrimental interaction with Dys deficient 
genotype. 
From this studies we can conclude that both OXT than CRF(6-33) have the potential to be used for 
treatment, respectively of social and impulsivity deficits. For OXT so far we observed a positive 
interaction with Dys deficient genotype , that needs to be confirmed in other schizophrenia relevant 
mouse models of social deficits. CRF(6-33) so far has demonstrated only to improve social 
performance in WT mice. The preliminary study on mutated mouse,if confirmed, seems to suggest 
that it might worsen the phenotype in presence of certain genetic mutations. It should be important 
to define mechanisms of interaction of CRF(6-33) with genetics as to define when it could be 
positively used for therapy and when it shouldn’t in a view of a genetic driven personalized 
schizophrenia therapy  
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Aim of the thesis 
The general aim of the studies described in this thesis is to investigate behavioral eﬀects produced by 
intranasal administrations of two different peptides in mice. In particular, we focused on oxytocin 
(OXT) and CRF(6-33) as potential therapeutic agents for social and cognitive impairments relevant to 
schizophrenia, respectively. Similarly to autism, the intranasal administration of OXT is attracting an 
increasing world-wide interest as an appealing treatment for, at least, some social/negative 
symptoms in schizophrenia. However, our own work (Huang et al., 2014) and other preclinical and 
clinical studies (K L Bales et al., 2014; Horta de Macedo, Zuardi, Machado-de-Sousa, Chagas, & Hallak, 
2014) are starting to alert that OXT treatment might not be beneficial to the overall population. Thus 
here we aimed to better investigate the use of intransal OXT based on different genetic backgrounds 
Furthermore, while preliminray pre-clinical studies showed promising procognitive improvements 
following of CRF(6-33)administrations , (Stephen C. Heinrichs & Joppa, 2001; Stephen C. Heinrichs, 
2003; Koob & Bloom, 1985),these studies were only done by intraceroventricular administration. This 
route of administration is suitable only for research use, just to test potential efficacy of the molecule 
or to study general functions of the system involved. However ICV administration has really poor 
transaltional valence to human studies, as it is a really invasive procedure. Thus, here we tested it 
intranasally; being first time this molecule was tested by this route we choosed to assay effects in in 
5-CSRTT as it is a quite sensible test for cognitive functions that permits to perform many different 
manipulations and to evaluate many aspects of cognition. A better  implementation of intranasal OXT 
administration in mice will help clarify the mechanism of action of OXT and dissect therapeutic 
potentials in relation to psychiatric disease characterized by social impairment. So far there is no 
therapeutic agents for schizophrenia-associated cognitive impairment, implementation of intranasal 
administrations for CRF(6-33) Might provide us a new and valuable therapeutic tool for targeting such 
kind of impairment, define drug genetic interaction in genetic mutated murine models and, 
moreover, easily translate results to humans, as intranasal administration is suitable for human 
treatment too. 
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Chapter 1 
General Introduction 
1.1 Schizophrenia 
Schizophrenia is a chronic, debilitating neuropsychiatric disorder typified by positive symptoms 
(hallucinations, delusions, disordered thoughts and behaviours), negative symptoms (blunted aﬀect, 
alogia, anhedonia, asociality, avolition) and cognitive deﬁcits (Kvajo, McKellar, & Gogos, 2012; Lewis & 
Gonzalez-Burgos, 2006). Aﬀecting about 1% of the world’s population, it is a mental illness which, 
globally speaking, represents one of the ten most important causes of long-term disability (Mueser & 
McGurk, 2004). 
The etiology of this devastating disorder is complex and still largely un-known. Stemming from the 
evidence found within the findings of family and twin studies, the correlation between schizophrenia 
and a strong genetic component is undoubtedly clear: having an aﬀected family member substantially 
increases the risk of developing schizophrenia and this risk increases in turn as the degree of genetic 
aﬃnity with the aﬀected family member increases (Tandon et al., 2008). However, it has been diﬃcult 
to ﬁnd the ’culprit’ gene, so to speak, as several common risk alleles of small eﬀect and/or rare but 
penetrant copy number variations are involved and have been found to confer only a slight increase 
in risk (odds ratio<2) (M Burmeister, 1999; O’Tuathaigh, Desbonnet, Moran, & Waddington, 2012; 
Tandon et al., 2008). Despite the results obtained from numerous genome-wide association studies 
(GWAS), even the common risk alleles for schizophrenia proved to be inconsistent due to the 
impossibility of replication in multiple populations (Margit Burmeister, McInnis, & Zöllner, 2008). A 
further complexity is shown by the interaction of epigenetic and environmental factors with the 
multiple susceptibility genes, which ostensibly may lead involved also interact with to increase the risk 
for the disorder development (Mueser & McGurk, 2004; O’Tuathaigh et al., 2012). 
Animal models that recapitulate the full phenotypic spectrum of neuropsychiatric disorders, such as 
schizophrenia, are impossible;  nevertheless these models are indispensable to our understanding of 
the predisposing causal factors underlying these disorders and to pemit to generate novel, 
mechanism-based and personalised treatments and the study of the biological role of the genetic 
variants implicated in Genome-Wide Association Studies (GWAS) of schizophrenia (Arguello & Gogos, 
2006). 
Moreover, data from animal models are much more sensible in detection as they simplify the system 
in a neutral genetic background. Animal models permits to isolate effects of single gene mutation or 
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to provide information of interaction of specific susceptibility genes.  Thus, data from animal studies, 
if taken together with human data, can help in the identification and prioritisation of the candidate 
genes. (Ayalew et al., 2012). 
Genetically modiﬁed mouse models for genes relevant to schizophrenia could validate the research 
construct and try to give support to the comprehension of the function of genes and their 
contribution to the pathophysiology of cognitive/schizophrenia-related abnormalities (Nestler & 
Hyman, 2010b; Papaleo, Lipska, & Weinberger, 2012) 
In particular, being deﬁcits in social functioning representative of a core negative symptom in 
schizophrenia (Tandon et al., 2008), social interaction in transgenic mouse models may constitute an 
easily-accessible index of negative symptomatology (Kirby, Waddington, & O’Tuathaigh, 2010). 
Moreover, cognitive symptoms can be eﬀectively modelled in transgenic mice and these mouse 
models will allow for both elucidation and in-vivo characterisation of the relationship between the 
speciﬁc genes and cognitive dysfunction. 
On top of that, due to the lack of eﬀective pharmacotherapies for social and cognitive dysfunction in 
schizophrenia, the need for better animal models is heightened: while existing typical and atypical 
anti-psychotic drugs proved eﬀective in reducing severity of positive symptoms, they show little or no 
effect against negative symptoms or social and cognitive impairments (Arguello & Gogos, 2006; Kvajo 
et al., 2012). 
The main mechanism concerning the therapeutic eﬃcacy of most ﬁrst-generation anti-psychotic 
drugs (a.k.a. typical) is an attenuation in dopamine-mediated neurotransmission through antagonism 
(or weak partial atomism) of dopamine D2 receptors. Un-fortunately, this dopaminergic blockade 
could lead to severe motor or extrapyramidal Parkinson-like adverse eﬀects (tardive dyskinesia, 
bradykinesia, tremors, muscle rigidity, and postural instability) (Gobira, Ropke, Aguiar, Crippa, & 
Moreira, 2013; Nestler & Hyman, 2010b). 
Second-generation (atypical) antipsychotics (clozapine, risperidone, olanzapine, quetiapine, etc) prove 
to less likely cause neurological side effects but are more liable to have different side effects and 
contribute to both an increase in weight and adverse metabolic effects, that is insulin resistance and 
dyslipidemia (Kane & Correll, 2010). 
  Provided that we are currently limited in pharmacological treatments for negative symptoms and the 
urgency of finding some effective treatments for these deficits prevents us from taking many other 
further clues into consideration for the result-oriented treatment of schizophrenia-related social and 
cognitive impairments, the availability of carefully-validated animal models, through which 
developing and screening of novel therapeutic agents, could greatly enhance functional recovery of 
patients(Davis et al., 2013; Neill et al., 2010). 
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Growing evidence indicates that risk genes associate with speciﬁc features of schizophrenia pathology 
(O’Connell, Lawrie, McIntosh, & Hall, 2011). For instance, studies suggest that variations in the 
dystrobrevin-binding protein 1 gene (DTNBP 1) are associated with severity of negative symptoms and 
cognitive dysfunction in schizophrenic patients (Burdick et al., 2007; DeRosse et al., 2006; Fanous et 
al., 2005; Straub et al., 2002). In this context, risk genes have the potential to serve as biomarkers by 
providing an index of an individual’s pathologic proﬁle, and then lead to increased speciﬁcity in clinical 
testing and the development of more personalised therapies (O’Connell et al., 2011). 
1.2 Intranasal administration of neuropeptides 
A steadily increasing amount of attention has been paid to the intranasal route of administering 
substances recently. Stemming from a mere search among the academic articles, one could certainly 
notice that by now almost 13,000 scientific papers dealing with intranasal-administration of a large 
variety of substances have been published (Veening & Olivier, 2013). Peculiarly, promising potential 
for the treatment of brain diseases is held by intranasal administration of neuropeptides, since it 
might deliver concentrations to the brain which have proven to be effective at a biological level 
without causing potent systemic hormone-like side effects (Born et al., 2002).  
In rats and mice, intranasal administration of vasopressin (AVP) and of OXT have been reported to be 
the starting point leading to the increase (both in the cerebrospinal fluid and selected brain regions) 
of the intracerebral concentration of these peptides, (Born et al., 2002; Neumann et al., 2013). 
Nevertheless, AVP/OXT endogenous release mediated by peripheral mechanisms are a likely to cause 
central effects (Ludwig et al., 2013); without a doubt, central effects are observed in humans after 
intranasal administration, regardless of the mechanism(s) involved (Veening & Olivier, 2013). 
Basically, substances applied on the mucosal wall of the nasal cavity do have three plausible paths to 
reach the cranial cavity and sections of the brain itself. Since these routes-of-access do not exclude 
each other, they are worth to be described in brief as the real measure of efficacy of neuropeptides 
exploiting selectively one or a combination of these possible mechanisms. These possibilities are: (1) 
intra-axonal and transneuronal transport mechanisms via the olfactory pathways; (2) via the 
peripheral blood stream and the Blood-Brain-Barrier (BBB) after crossing the mucosal walls of the 
nasal cavity; (3) via perineuronal and other spaces along the olfactory fibers and other cranial nerves 
to enter the arachnoid space and Cerebrospinal fluid (CSF) surrounding the brain. 
Neuroanatomical tracers can be conveyed from the olfactory sensory neurons (OSN), as stated within 
several studies in the rat, in the epithelium covering both the nasal cavities to the olfactory bulb and 
all second order olfactory regions after transneuronal transport, . Ostensibly, transport occurs in both 
anterograde and retrograde directions, which brought out all central olfactory connections (Shipley, 
1985). these findings were confirmed in other species both such as rat at the electronmicroscopical 
level (Baker & Spencer, 1986) and in mice at a genic level through the transfer of a plant lectin as a 
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transneuronal tracer in transgenic mice to target the olfactory system and study its connectivity 
(Horowitz, Montmayeur, Echelard, & Buck, 1999).  
Being it is painfully slow and without justifying  the fastness of observed effects by intranasal 
administration , this way is rather not likely to be the main way dealing with intranasal brain 
administration of neuropeptides , and the distribution to brain not exclusively limited to olfactory 
areas (Veening & Olivier, 2013) 
Concerning a peripheral transport via the blood stream after crossing the nasal mucosa an already 
existing functional pathway between the nose and the brain must be taken into consideration, in that 
it appears to be a chemical exchange between venous and arterial vessels. Substances such as 
neuropeptides, progesterone, tritiated water, tyrosine, propanol and diazepam, and alike are 
transferred from the nasal cavity into these cranial arteries, sprouting from the internal carotid 
artery.(Veening & Olivier, 2013). Notwithstanding the molecules flow into the cerebral blood circle, 
thanks to the  good functionality of the BBB, which blocks the entrance of 98% of small and nearly 
100% of large molecules ( and the elevated levels of substances in specific brain vessels), it does not 
mean that more of the substance involved enters either the brain or the extracellular spaces, (Dhuria, 
Hanson, & Frey, 2010; Pardridge, 2005). As a general rule, this makes it highly improbable that ‘nasal 
delivery’, occurs via the general circulation. Nevertheless, it has to be kept in mind that under certain 
conditions and for certain substances, the systemic- routecontributions may play some role in the 
effects of intranasal -administration observed, especially if the substances cross the BBB rather easily. 
Various studies agree that additional transport pathways, extra-axonal and extra-systemic and 
therefore called ‘direct’, must exist between nasal and cranial cavities and/or between olfactory 
epithelia and olfactory and possibly other brain areas and/or the CSF-containing arachnoid space 
(Dhuria et al., 2010; Sakka, Coll, & Chazal, 2011). A great many findings provide evidence for the 
existence of such additional pathways.  
‘Rapid access’: several substances arrive at the olfactory brain regions considerably faster than 
expected on the basis of systemic or intra-axonal transport mechanisms. Arrival times of less than a 
minute have been observed for the olfactory bulbs (Born et al., 2002; Charlton et al., 2008; Illum, 
2004; Thorne, Pronk, Padmanabhan, & Frey, 2004) while the highest brain levels after systemic 
administration as well as after intra-axonal transport are reached considerably later, up to hours in 
the case of intra-axonal transport (Dhuria et al., 2010). 
While the data in favour of ‘direct pathways’ from the nasal to the cranial cavity may be rather 
convincing, many questions remain unanswered questions, both at the electronmicroscopical and at 
functional anatomical levels. Many details about these pathways or ‘entrance- routes’ are not fully 
elucidated yet. 
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Abstract 
The dysbindin-1 gene (dtnbp 1) has been identified as one of the leading susceptibility genes for 
schizophrenia. In the clinic, this risk gene has been associated with the severity of negative symptoms 
and cognitive deficits in schizophrenia. Using a dysbindin-1 (Dys) knockout mutant mouse model, we 
demonstrated that both the heterozygous and homozygous knockout mice manifested a reduction in 
social interaction compared to Dys wildtype mice. This is in agreement with other groups' 
observations of reduced social contacts in the Sandy (sdy) mouse, which harbours a spontaneuosly 
occurring deletion in the dtnbp 1 gene and expresses no Dys protein. However, in contrast to its 
effects in C57 wildtype mice, chronic intranasal administration of oxytocin (OXT) was able to 
ameliorate the social deficits observed in heterozygous but not in homozygous Dys knockout mice. 
Furthermore we demonstrated that acute administration of oxytocin was able to improve social 
deficits both in hetero and in homo Dys KO mice. These results provide initial indication that, 
conversely to subjects with a healthy OXTergic system,  intranasal OXT produce prosocial effects in 
socially and OXTR altered systems with relevance to schizophrenia.  
2.1 Introduction 
 
The neuropeptide oxytocin (OXT) has been strongly implicated in social behaviours including social 
recognition, social approach, pair bonding, paternal care and maternal behaviour (Lim, Bielsky, & 
Young, 2005; Mariaelvina Sala et al., 2011b; Winslow & Insel, 2002). This has led to the proposal of its 
use as an adjunctive therapeutic treatment in neuropsychiatric diseases characterized by impaired 
social behaviours such as social anxiety disorder, borderline personality disorder, autism spectrum 
disorders and schizophrenia (Meyer-Lindenberg et al., 2011; Striepens et al., 2011). This would be 
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particularly important as social alterations are considered among the most debilitating core features 
of these mental illnesses and currently available treatments are not effective in ameliorating these 
symptoms. Intranasal administration of neuropeptides holds promising potential for the treatment of 
brain diseases as it might deliver biologically effective concentrations to the brain without eliciting 
potent systemic hormone-like side effects (Born et al., 2002). Intranasal administration of vasopressin 
(avp) and of OXT have been reported, in rats and mice, to increase the intracerebral concentration of 
these peptides, not only in the cerebrospinal fluid but also in selected brain regions (Born et al., 2002; 
Neumann et al., 2013). However, central effects might be also due to avp/OXT endogenous release 
mediated by peripheral mechanisms (Ludwig et al., 2013). Whatever the mechanism(s) involved, 
there is no doubt that central effects are observed in humans after intranasal administration (Veening 
& Olivier, 2013). Acute intranasal OXT seems to produce no negative side effects in both healthy 
volunteers and subjects with developmental or mental health difficulties when delivered in doses of 
18-40 IU (MacDonald et al., 2011). Moreover, in subjects diagnosed with autism, a single intranasal 
administration of OXT might be able to improve, at least temporarily, emotion recognition abilities in 
the Reading the Mind in the Eyes test and the patients' ability to process socially relevant cues in a 
computer-based game (Andari et al., 2010; Green & Hollander, 2010; Guastella, Mitchell, & Dadds, 
2008). Furthermore, in patients with schizophrenia, an adjunctive 3-week treatment with intranasal 
OXT has been found to improve Positive and Negative Syndrome Scale (PANSS) total scores 
significantly (Feifel et al., 2010) and verbal memory measures of the California Verbal Learning Test 
(Feifel, Macdonald, Cobb, & Minassian, 2012). Despite these promising initial results, it is not yet clear 
if chronic intranasal OXT might affect psychiatric-relevant behavioural measures (e.g. in social and 6 
memory domains), and if chronic intranasal OXT has different effects compared with single 
administration. This is critical for the aforementioned chronic mental disorders that might potentially 
involve life-long treatments. Unfortunately, ethical issues, genetic, environmental and clinical 
heterogeneity in human studies might dampen the resolution of these questions and thus, slow down 
the progress towards this new promising therapeutic treatment. In this context, preclinical studies in 
rodents might be critical to dissect OXT-dependent behavioural effects and hold the potential to 
better understand the impact of intranasal OXT in brain functioning. Just recently was demonstrated 
in our lab possibility to use intranasal administrations in mice so now we have Recently introduced 
the possibility to test intranasal OXT treatments (Huang et al., 2014) for large genetic and 
pharmacological screenings aiming at developing more selective and personalized therapeutic 
strategies for human pathologies such as autism and schizophrenia. The role of the OXT system has 
been investigated in rodent models mainly using OXT-related mutant mice and giving OXT through 
intracerebroventricular (ICV), intraperitoneal (ip) and subcutaneous (sc) injections (Bielsky & Young, 
2004; Jin et al., 2007; Popik, Vetulani, & Van Ree, 1996; Mariaelvina Sala et al., 2011b, 2013; 
Takayanagi et al., 2005; Winslow & Insel, 2002). Before our previous work (Huang et al., 2014) only 
one study in prairie voles (Microtus ochrogaster) (Karen L Bales et al., 2013) has initiated to 
investigate the behavioural effects of intranasal OXT administration before adulthood (i.e. from 
weaning through sexual maturity); after that study, intranasal oxytocin was still used just in other two 
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studies in mice (K L Bales et al., 2014; Gigliucci et al., 2014) even if both times just in models for 
autism. Thus, the present study aimed at elucidating the behavioural effects of intranasal 
administration of OXT in adult mouse model relevant for schizophrenia, and the Dysbindin-1 deficitary 
mutant mouse model was chosen for this test . 
Dysbindin-1 (Dys) is encoded by the Dystrobrevin-binding protein 1 gene (DTNBP 1) and is expressed 
widely in human and mouse brains (Burdick et al., 2006). Dysbindin-1 has been implicated in the 
regulation of vesicle formation and synaptic release (Chen et al., 2008; Dickman & Davis, 2009) and is 
a component of the biogenesis of lysosome-related organelles complex (BLOC-1) (Iizuka, Sei, 
Weinberger, & Straub, 2007). Recent studies in mice show that Dysbindin-1 is more highly expressed 
during embryonic and early postnatal development compared to adulthood and bloc-1 is involved in 
neurite outgrowth (Ghiani et al., 2010). These findings point to a potential role of Dysbindin-1 in 
normal development of brain structure and function. In addition, abnormalities in Dysbindin-1 have 
been found to also affect cognition in humans as well as in mice, and variations in the DTNBP 1 gene 
are associated with alterations in general cognitive abilities (Burdick et al., 2006; Fallgatter et al., 
2006; Papaleo & Weinberger, 2011; Papaleo, Yang, et al., 2012) such as; selective attention, general, 
verbal, sometimes visual memory measured on the revised Wechsler Memory Scales (Hashimoto et 
al., 2009, 2010), working memory, verbal declarative memory, mental processing speed, executive 
function measured with multiple tests (Luciano et al., 2009; Markov et al., 2010), and semantic verbal 
fluency (Markov et al., 2009). Genetic variations (single nucleotide polymorphisms; SNPs and/or 
combinations of them; haplotypes) in DTNBP 1 is also associated with psychiatric conditions. (Straub 
et al., 2002) first identified an association between schizophrenia and several SNPs within the DTNBP 
1 gene, in a linkage disequilibrium study across the 6p24-21 susceptibility interval. Subsequent studies 
have since confirmed this association in multiple, independent populations (Schwab et al., 2003; Van 
Den Bogaert et al., 2003) and DTNBP 1 remains among the leading candidate genes in meta-analyses 
(Allen et al., 2008). Schizophrenic patients have been reported to have reduced expression of 
Dysbindin-1 gene and protein in the prefrontal cortex (PFC) and hippocampus, regions associated with 
Dysfunction of executive control and working memory functions in the disorder (Talbot et al., 2004; 
Tang et al., 2009; Weickert et al., 2004; Weickert, Rothmond, Hyde, Kleinman, & Straub, 2008) but the 
molecular mechanisms by which this contributes to pathogenesis and symptomatology are as yet 
unknown (Iizuka et al., 2007). Association studies have also implicated DTNBP 1 variation in the 
severity of negative symptoms and cognitive impairments in schizophrenia (Burdick et al., 2007; 
DeRosse et al., 2006; Fanous et al., 2005; Straub et al., 2002). The Sandy (sdy) mouse (Figure 1), which 
has a naturally occurring deletion mutation of exons 6 and 7 in the gene (DTNBP 1) encoding the 
mouse protein, provides an animal model of Dysbindin-1. The mutation results in loss of Dys in 
homozygous animals. Dysbindin-1 knock-out (Dys-/-) mice show selective alterations in internal 
trafficking of specific components of dopamine and glutamate signalling, including D2 receptors and 
NR2A receptor subunits (Karlsgodt et al., 2011; Papaleo, Yang, et al., 2012). Cortical neuronal cultures 
from Dys-/- mice show signalling alterations that may underlie the deficits in cognitive performance. 
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In particular, Dysbindin-1 has been associated with various aspects of synaptic function (Cox et al., 
2009; Dickman & Davis, 2009), and the regulation of both dopamine and glutamate signalling in the 
brain (Papaleo & Weinberger, 2011). Results from in-vitro experiments suggest that Dysbindin-1 
suppresses dopamine release (Kumamoto et al., 2006) and cultured neurons from Dys-/- mice have 
increased cell surface expression of the D2 receptor due to an increased membranal insertion rate (Ji 
et al., 2009). Layer II/III pyramidal neurons from the PFC of Dys-/- mice show increased activity at 
baseline, but decreased activity after D2 stimulation compared to wild-type mice and these effects 
may be due to D2-mediated alterations in the excitability of fast-spiking GABA ergic interneurons (Ji et 
al., 2009; Papaleo, Yang, et al., 2012). Reduced Dysbindin-1 function also impairs glutamate signalling 
in neuronal culture (Numakawa et al., 2004). In agreement with these in-vitro studies, sdy mice 
display decreased excitability of glutamatergic neurons in the PFC and a decrease in the release of 
glutamate in the hippocampus (Chen et al., 2008; Jentsch et al., 2009). Furthermore, recent work 
demonstrates that Dys-/- mice exhibit reduced NMDA-evoked currents and reduced NR 1 mRNA 
expression in the PFC (Karlsgodt et al., 2011). Dys-/- mice also show cognitive impairments, for 
example; spatial memory deficits in the Morris water maze (Cox et al., 2009), working memory 
deficits in a discrete paired-trial T-maze task (Papaleo, Yang, et al., 2012) and in a delayed non-match-
to-position operant task (Karlsgodt et al., 2011). Taken together, these data implicate a reduction of 
Dysbindin-1 function thought to play a role in the development of cognitive abnormalities found in 
schizophrenia. Therefore, the Dys null mutant mice represent an important model of Dysbindin-1 
down-regulation and D2 up-regulation that will help unravel the molecular mechanism for the 
association of Dysbindin-1 with psychosis, social and cognitive deficits (Papaleo, Yang, et al., 2012). In 
a previous work (Huang et al., 2014), was shown that chronic intranasal oxytocin (OXT) treatment in 
wild-type C57BL/6J adult mice produced a selective reduction of social behaviours concomitant to a 
reduction of the OXT receptors throughout the brain. These results indicate that a prolonged over-
stimulation of a "healthy" oxytocinergic brain system, with no inherent deficits in social interaction 
and normal endogenous levels of OXT caused specific detrimental effects in social behaviours. In view 
of the literature that show sdy mutant mice with a deletion in DTNBP 1, exhibit deficits in social 
interaction, the purpose of the following experiments was to test whether acute and chronic 
intranasal OXT treatment could ameliorate these deficits.  
The genetic background strain chosen for the study C57BL/6j is a classical background strain for 
genetically modified mice and animal models of neurodegenerative and neurodevelopmental 
disorders. In line with clinical settings where intranasal OXT treatments would be mainly administered 
to address chronic symptoms in psychiatric disorders, we first performed behavioural and molecular 
studies in mice undergoing chronic intranasal treatment and thereafter, also separately tested the 
effects of acute intranasal OXT treatment.  
.  
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Figure 1: From top: First 2 pictures show the coat-color difference between wild type and sdy homozygous mice 
due to defective melanosome formation. Second picture shows the basic exonic-intronic structure of mouse 
DTNBP 1 gene showing large deletion mutation of exons 6 and 7 in sdy mice reported by (Li et al., 2003). Third 
picture shows a schematic of dysbindin-1 lacking 52 amino acids in the coiled coil domain due to mutation-
induced truncation of transcript. The last picture shows dysbindin-1A decrease and loss in kidney tissue of 
heterozygous and homozygous animals, respectively (Li et al., 2003), probably due to rapid degradation as a 
result of failure to form stable interactions with bloc-1 binding partners in the absence of an intact coiled coil 
domain. [Modified from (Talbot, 2009).]  
2.2 Materials and Methods 
 
2.2.1 Subjects 
 
All procedures were approved by the Italian Ministry of Health (permit n. 230/2009-B) and local 
Animal Use Committee and were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health and the European Community Council 
Directives. Sandy (sdy) is an autosomal recessive coat mutation that occurred spontaneously in the 
inbred DBA/2J strain in 1983 at The Jackson Laboratory. The mutation present in our mice was 
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transferred to the C57BL/6J (B6) genetic background by 11 generations of backcrossing into B6 at The 
Jackson Laboratory and National Institute of Mental Health. The purpose of this backcrossing 
procedure was to remove the effects on behaviour and dopamine function of the native sdy mouse 
background strain (DBA/2J), which has been shown to have abnormal behavioural phenotypes 
referable to the dopamine system (D’Este, Casini, Puglisi-Allegra, Cabib, & Renda, 2007). In particular, 
previous reports have shown that on the DBA/2J genetic background, sdy mice exhibit strong 
locomotor activity and coordination deficits, as demonstrated by poor performance in the rotarod 
test and even death during a forced swimming test (Takao et al., 2008). Also, DBA/2J mice are 
impaired in θ burst long-term potentiation, in aspects of learning and memory, have higher 
dopaminergic activity in the forebrain, and are homozygous for four other mutations (cadherin, 
glycoprotein, tyrosinase-related protein 1 and hemolytic complement) compared with B6 mice (Cox et 
al., 2009; D’Este et al., 2007; Nguyen, 2000). Therefore, the role of the dysbindin-1 mutation is 
potentially confounded when studied on the DBA/2J genetic background (Talbot, 2009). In these 
experiments, we used male littermates that were dysbindin-1 null mutant (Dys-/-), heterozygous 
(Dys+/-), and wild-type (Dys+/+) bred by a heterozygous (Dys+/- Dys+/-) mating strategy. Genotypes 
were identified by pcr analysis of tail dna. Animals were housed two to four per cage, in a climate-
controlled animal facility (22°C ± 2°C) and maintained on a 12-hour light/dark cycle, with food and 
water available ad libitum throughout the experiments. All behavioural testing and procedures were 
conducted during the light phase of the cycle. The experimenter handled the mice on alternate days 
during the week preceding the first behavioural test. Experimenters were blind to the mouse 
treatments during testing and behavioural scoring.  
 
2.2.2 Intranasal OXT Administration 
 
Oxytocin (Novartis Pharma AG, Switzerland) was dissolved in saline (0.9% NaCl) and administered 
intranasally in a volume of 5µl to each mouse in dose of 0.3 IU/5 µl (OXT 0.3 IU). In our solution 1 IU of 
oxitocyn is equal to 1.667 μg of synthetic OXT. Thus, 0.3 IU corresponded 0.5001 µg (≈4.96 x 10-7 mol) 
of oxytocin, for each administration of 5 µl (OXT 0.3 IU ≈ 19 µg/kg or 11 IU/kg). This dose was chosen 
in order to be much lower than subcutaneous oxytocin doses (i.e. 250 µg/kg) used in mice that could 
have produced peripheral effects(Mariaelvina Sala et al., 2011b). The dose we used was also similar to 
the higher range of intranasal oxytocin doses recently given to adolescent prairie voles (Karen L Bales 
et al., 2013) and furthermore resulted to be effective in previous works. (Huang et al., 2014). A 20 µl 
Eppendorf pipette with gel-loading tips (Costar no. 4853) were used for administration. Drops of the 5 
µl solution were gently placed equally on both nostrils of each mouse, and whose were inhaled 
reflexively. Control mice received the same volume of saline (veh). Administration was rapid (less than 
30 seconds) and handling was consistent across treatment groups. The detailed timelines of each 
procedural manipulation and oxytocin treatments are reported in Figure 2 Briefly, for the chronic 
intranasal treatments, mice were administered two times a day, once in the morning and once in the 
evening, for 7-21 consecutive days and tested as described below, one hour after the last 
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administration. For the acute intranasal treatments, mice were administered with OXT only once, 5 
minutes before the test. The delay of only 5 minutes was chosen based on evidence indicating that 
intranasal administration of OXT has very rapid pharmacokinetics with effects expected to appear 
already within a few minutes (Veening & Olivier, 2013).  
 
 
Figure 2 Experimental timelines. (a) Naive and Chronic 7 days of IN VEH or OXT in treatment. (b) Chronic male-female 7 
days of IN VEH or OXT in treatment.(c) Brain autoradiography after 7 days of 7 days of IN VEH or OXT in treatment. (d) 
Single acute IN dose VEH 
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2.2.3 Behavioural Testing 
 
Male-Female social interaction test 
 
The test was conducted in 2150E Tecniplast cages (35.5×23.5×19 cm) lightly illuminated (5±1 lux) and 
video-recorded using a Unibrain Fire-iTM Digital Camera. The video camera was mounted facing the 
front of the cage to record the session for subsequent scoring of social investigation parameters as 
previously described (M L Scattoni, Ricceri, & Crawley, 2011). Unfamiliar female stimulus mice in 
oestrus were matched to the subject male mice by age and maintained in social groups of four per 
home cage. In a subgroup of animals, ultrasonic vocalisations (usvs) were also recorded during the 
test. 
All the equipment was kept in a sound-attenuating chamber (TSE Multi Conditioning Systems). 
Each male mouse was placed in a test cage and left to habituate for one hour before the test. Then, 
an unfamiliar female in oestrus (stimulus mouse) was placed into the testing cage of each isolated 
male for a 5-min test session. In addition to the resident mouse, the cage contained litter (1.5-cm 
deep) while the lid was removed during the test. Female stimulus mice were matched to the subject 
male mice by age and maintained in social groups of four per home cage. 
On the day of testing, the vaginal oestrus condition of each female was assessed as previously 
described (Rugh, 1990). Only females in oestrus were selected for the test. Behavioural responses 
were analysed by NOLDUS OB-SERVER XT 10 software (Noldus Information Technology, Leesburg, VA, 
USA). 
Social interaction was scored from the recorded videos measuring frequencies and durations of the 
following behavioural responses performed by the male mouse: 
1. Social behaviours: anogenital sniﬃng (direct contact with the anogenital area), body sniﬃng 
(sniﬃng or snout contact with the ﬂank area), head sniﬃng (sniﬃng or snout contact with the 
head/neck/mouth area) and following (time spent in following the female mice). 
2. Non-social behaviours: stand/walk alone, digging in the bedding, grooming (self-cleaning and 
licking any part of its own body), rearing up in the centre of the cage and rearing up against 
the wall of the home cage. 
3. Total social behaviour and total non-social behaviour were obtained by summing up frequency 
or duration of all social behaviours and all non-social behaviours as listed above, respectively. 
No observations of wrestling behaviours were observed during the male-female interaction test. 
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Habituation/Dishabituation social interaction test 
Naive mice were tested as similarly reported previously (Ferguson et al., 2000; Huang et al., 2014; 
Scearce-Levie et al., 2008) in 2150E Tecniplast cages (35.5x23.5x19 cm) lightly illuminated (5±1 lux) 
and video-recorded using a Unibrain Fire-I TM Digital Camera. Male or female subject mice were 
individually placed in the testing cage 1 hour before the testing. No previous single housing 
manipulation was adopted to avoid any instauration of home-cage territory and aggressive behaviors. 
Testing began 5 minutes after the intranasal treatment when a stimulus same sex mouse was 
introduced into the testing cage for a 1-min interaction. At the end of the 1-min trial, we removed the 
stimulus animal and returned it to an individual holding cage. We repeated this sequence for three 
trials with 3-min inter-trial intervals introducing the same stimulus mouse in all four trials. In a fifth 
`dishabituation' trial, we introduced a new unfamiliar stimulus mouse (as previously of the same sex 
of the subject) in the testing cage. Videos of behaviors were recorded and subsequently manually 
scored offline.  
2.2.4 Brain autoradiography 
 
A separate cohort of naive mice was handled and intranasally treated with vehicle or oxytocin as 
described above and, at the same time-point when the social interaction test would have been 
performed, their brains were rapidly dissected and frozen in isopentane at -25°C and then stored at -
80 °C. Brains were cut in coronal sections of 14-µm thickness and mounted on chrome-alum-gelatin 
coated microscope slides. All slides were stored at -80 °C until used in receptor autoradiography. The 
binding procedure was performed as previously described (Tribollet, Barberis, & Arsenijevic, 1997). 
Brain sections were lightly fixed by dipping the slides for 5 min in a solution of 0.2% 
paraformaldehyde in 0.1 M phosphate-buffered saline (pH 7.4), then rinsed by two 5-min washes in 
50 mM Tris-HCl buffer (pH 7.4) supplemented with 0.1% bovine serum albumin. OXT binding sites 
were labelled with the radioiodinated OXT-receptor antagonist d(CH2)5[Tyr(Me)2,Thr4,Tyr9-NH2]OVT 
(125I-OVTA, Perkin Elmer, MA, USA) at 0.02 nM (Elands et al., 1988). AVP binding sites were labelled 
with the radioiodinated linear vasopressin, V1aR antagonist HO-Phaa1-D-Tyr(Me)2-Phe3-Gln4-Asn5-
Arg6-Pro7-Arg8-NH2 (125ILVA, Perkin Elmer, MA, USA) at 0.02 nM. The specific activity of 
radioligands was 2200 Ci/mmol; 1Ci=37 GBq). Non-specific binding was determined in the presence of 
2 µM OXT or avp. Binding was carried out in a humid chamber, at room temperature, by covering 
each slide with 400 µl of incubation medium (50 mM Tris-HCl, 0.025% bacitracin, 5 mM MgCl2, 0.1% 
bovine serum albumin) containing 125I-OVTA or 125I-LVA, either alone or in the presence of OXT or 
avp. Incubation lasted 1 hour at room temperature under gentle agitation and was followed by two 5-
min washes in ice-cold incubation medium and a quick rinse in distilled water. The slides were dried 
under a stream of cool air. Once dry, the slides were exposed to Biomax MR Films (Kodak) for 72 
hours. The quantification of optical binding density was conducted on the resulting autoradiograms 
images as previously described (Rubino, Forlani, Viganò, Zippel, & Parolaro, 2005). In particular, each 
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cerebral area was traced with the mouse cursor and its densitometric gray level was calculated by 
subtracting the background of the film using NIH ImageJ software. Optical densities were then 
converted to nCi/mg tissue equivalent with the standard curve generated by calibrated iodinated 
microscales (0.72-52.13 nCi/mg tissue equivalent, Amersham). The number of slides for each area 
varied, but averaged approximately ten sections per area.  
2.2.5 Automated scoring for familiar mice 
 
The test was conducted in an empty open arena with opaque grey walls (40×40×40 cm) and dimly 
illuminated by overhead red lightning (mainly to facilitate mice handling by the experimenter). Mice 
were monitored by an infrared camera mounted 1.5 m above the arena. The camera was a FLIR A315 
capable of a spatial resolution of 320×240 px at 30fps, with a thermal sensitivity of <0.05°C at+30°C 
(according to the producer) that allows full video recording even in full darkness. All the animals were 
recorded without any external artificial tagging (such as coloured paintings). 
 
Analyses of social behaviour was performed by an automated tracking and social behaviour analisis 
system previously described in (Giancardo et al., 2013). 
 
2.2.6 Statistical analyses 
 
Results are expressed as mean ± standard error of the mean (sem) throughout. One- or two-way 
analyses of variance (anovas) were used for each single parameter measured. Newman-Keul's post-
hoc test was used for making comparisons between groups when the overall anova showed statistical 
significant differences for the main factors. The accepted value for significance was p ≤ 0.05. All 
statistical analyses were performed using the Statistica version 11 software (Statistica, StatSoft, Inc.).  
2.3 Results 
 
2.3.1 Social deﬁcits in Dysbindin-1 mutant mice 
A signiﬁcant genotype eﬀect was evident in anogenital sniﬃng (frequency: F2,25=4, p<0.05; duration: 
F2,25=7.85, p<0.005). In particular, compared with the Dys+/+ group, Dys+/- male mice showed 
decreased duration of anogenital sniﬃng events (p<0.05; Fig. 3.2b). Additionally, for the Dys-/- group, 
there was a signiﬁcant decrease in the number of anogenital sniﬃng events (p<0.05; Fig. 3.2a) and in 
their duration (p<0.005; Fig. 3.2b) relative to the Dys+/+ group. 
No signiﬁcant eﬀect of genotype was observed in other measures of social interaction such as head 
sniﬃng (frequency: F2,25=1.09, p=0.35; duration: F2,25=1, p=0.55), body sniﬃng (frequency: F2,25=1, 
p=0.35; duration: F2,25=1.74, p=0.20), following (frequency: F2,25=2, p=0.16; duration: F2,25=1.99, 
p=0.16). (Figure 3a, 4b). 
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Similarly, in comparison with the Dys+/+ group, both Dys+/- and Dys-/-groups showed no signiﬁcant 
diﬀerences in the non-social behaviours such as digging (frequency: F2,25=0.31, p=0.73; duration: 
F2,25=0.36, p=0.70), and wall rearing (frequency: F2,25=2, p=0.23; duration: F2,25=1.21, 
p=0.31).(Figure 3c, Figure 3d). 
Overall, there was a significant effect of genotype in the duration of social behaviours (F2,25=8.63, 
p<0.005), but not in the number of social behaviour events (frequency: F2,25=3, p=0.08; Fig. 3.2e), 
nor in non-social behaviours (frequency: F2,25=1, p=0.34; duration: F2,25=0.37, p=0.70). In particular, 
post-hoc tests showed a decrease in the duration of social behaviours in both the Dys+/- (p<0.05) and 
Dys-/- groups (p<0.005) compared with Dys+/+ mice (Figure 3f). 
During the male-female social interaction test, it is also possible to record usvs emitted by the male 
mice that are considered facets of social communication among rodents (M L Scattoni et al., 2011; 
Maria Luisa Scattoni, Crawley, & Ricceri, 2009). There was a significant effect of genotype in the total 
number of vocalisations emitted (F2,25=5.62, p<0.05). In particular, both the Dys+/- and Dys-/- groups 
of mice showed a decrease in the total number (p<0.05; Fig. 3.3) of vocalisations emitted compared 
to the Dys+/+ group. 
Overall, these ﬁndings indicate that a relative reduction or complete deletion of dysbindin-1 function 
produces a decrease in social interaction behaviours towards opposite-sex female mice. 
2.3.2 Social deﬁcits in Dys mutant mice are ameliorated by chronic intranasal oxytocin 
As discussed in chapter 2.1, the OXT system has been extensively involved in the modulation of social-
related behaviours (Bielsky & Young, 2004; M Sala et al., 2013; Mariaelvina Sala et al., 2011a; Winslow 
& Insel, 2002). Thus, in order to assess possible rescue eﬀects of chronic intranasal OXT treatment in 
the social deﬁcits that has been found in Dys knockout mutant mice (both heterzygous and 
homozygous knockouts), we tested mice chronically treated with intranasal OXT or veh in the male-
female social interaction test (M L Scattoni et al., 2011). A significant genotype effect was apparent 
for body sniffing (frequency: F2,28=8.15, p<0.005; duration: F2,28=9.23, p<0.005). Specifically, 
compared with the Dys+/+ veh-treated group, Dys+/- and Dys-/- veh-treated male mice showed 
decreased frequency and duration of body sniffing events (p<0.005;Figure 3 a. Figure 3 b). These 
results provides further confirmation of the social deficits that we have observed in the previous 
experiment (see above Section 2.3.3). 
In addition, a significant OXT-treatment effect is observed in the Dys+/-veh and OXT-treated groups 
for body sniffing (frequency: F2,28=3.81, p<0.05; Fig 3.4a) and anogenital sniffing (duration: 
F2,29=4.25, p<0.05; Fig 3.4b). In particular, both the Dys+/- 0.15 IU OXT and 0.3 IU OXT groups 
exhibited an increase in the number of body sniffing events (p<0.05; Fig 3.4a) and the Dys+/- 0.3 IU 
OXT group, an increase in the duration of anogenital sniffing events (p<0.05; Fig 3.4b) compared with 
the Dys+/- veh group. 
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No signiﬁcant genotype eﬀect has been found in the non-social behaviours, except for wall rearing 
(duration: F2,28=4.45, p<0.05; Fig 3.5b) where the Dys+/- veh group displayed an increase in the 
duration of wall rearing events (p<0.05) compared to the Dys+/+ veh group. 
However, a signiﬁcant eﬀect of OXT-treatment is observed in the Dys+/-veh and OXT-treated groups 
for rearing (duration: F2,29=6.94, p<0.005; Fig 3.5b) and wall rearing (frequency: F2,29=4.12, p<0.05; 
duration: F2,29=4.87, p<0.05; Fig 3.5a, 3.5b). Chieﬂy, the Dys+/- 0.15 IU OXT-treated mice showed an 
increase in the duration of rearing events (p<0.05) and a decrease in the number (p<0.05) and 
duration (p<0.05) of wall rearing events compared with Dys+/- veh-treated mice. Furthermore, Dys+/- 
0.3 IU OXT-treated mice also displayed a reduced duration of wall rearing events (p<0.05) in 
comparison to Dys+/- veh-treated mice. 
In summary, there was a significant genotype effect in the frequency of total social behaviours 
(F2,28=4.50, p<0.05; Fig 3.6a) but none in the duration of total social behaviours (F2,28=2.87, p=0.07) 
nor in total non-social behaviours (frequency: F2,28=0.43, p=0.66; duration: F2,28=0.88, p=0.42; Fig 
3.6a, 3.6b). Post-hoc tests revealed a decrease in the number of total social behaviours in Dys+/- and 
Dys-/- veh-treated mice with respect to Dys+/+ veh-treated mice (p<0.05). Furthermore, OXT 
treatment showed a significant effectin total social behaviours of Dys+/- OXT 0.15 IU and 0.3 IU 
groups (frequency: F2,29=3.16, p=0.05; duration: F2,29=6.71, p<0.005) and in the duration of total 
non-social behaviours (F2,29=3.78, p<0.05) but not in the frequency (F2,29=1.98, p=0.16). Specifically, 
the Dys+/- 0.15 IU OXT group exhibited an increase in the number of total social behaviours (p=0.05) 
and both Dys+/- 0.15 IU and 0.3 IU OXT groups showed an increase in the duration of total social 
behaviours (p<0.05) with respect to the Dys+/- veh group. On top of that, the Dys+/- 0.3 IU OXT group 
also displayed a decrease in the duration of total non-social behaviours (p<0.05) compared with the 
Dys+/- veh group. 
Statistical comparisons between the Dys+/- and Dys-/- OXT-treated groups with the Dys+/+ veh group 
revealed that there are no diﬀerences in the all of the measures of social behaviours between the 
groups, except for anogenital sniﬃng (Dys+/+ veh vs Dys+/- and Dys-/- 0.3 IU OXT groups: frequency: 
F2,29=4.32, p<0.05; duration: F2,29=3.96, p<0.05). Notably, post-hoc tests showed that the number 
of anogenital sniﬃng events of the Dys-/- 0.3 IU OXT group is reduced (p<0.05; Fig 3.4a) as compared 
to that of the Dys+/+ veh 
group, whereas the duration of anogenital sniﬃng events of the Dys+/- 0.3 IU OXT group is longer 
(p<0.05; Fig 3.4b) than that of the Dys+/+ veh group. These results indicate that chronic intranasal 
OXT treatment can potentially rescue the social deﬁcits that have been observed in Dys mutant mice. 
 
23 
 
 
Figure 3 Dys mice show a reduction in male-female social interaction. (a) Frequency of occurrence of 
various social behaviours such as head sniffing, body sniffing, angogenital sniffing and following. (b) Duration of 
events of above-mentioned social behaviours. (c) Frequency of occurrence of various non-social behaviours 
such as digging and wall rearing. (d) Duration of events of above-mentioned non-social behaviours. (e) Sum of 
the frequency of all events of social and non-social behaviours. (f) Sum of the duration of all events of social and 
non-social behaviours. (g) Total number of USV calls in 5 minutes. Ns= 7 Dys+/+, 10 Dys+/-, 10 Dys-/-. (*) 
p<0.05, (**) p<0.005 vs. Dys+/+ group. Values represent mean ± SEM throughout all Figures. 
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Figure 4 Chronic intranasal OXT treatment reverted reduction in total social behaviours in Dys 
heterozygous knockout mice. (a) Sum of the frequency of all events of social and non-social behaviours. (b) 
Sum of the duration of all events of social and non-social behaviours. Ns= 14 Dys+/+ VEH, 12 Dys+/- VEH, 7 
Dys-/- VEH, 10 Dys+/- OXT 0.15 IU/5 µl, 7 Dys-/- OXT 0.15 IU /5 µl, 12 Dys+/- OXT 0.3 IU/5 µl, 8 Dys-/- OXT 0.3 
IU/5 µl. 
(*) p<0.05, (**) p<0.005 vs. Dys+/+ VEH group. (#) p<0.05, (##) p<0.005 vs. Dys+/- VEH group. 
Values represent mean ± SEM throughout all Figures. 
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2.3.3 Disbindin mutations reduce interaction times in female mice 
In social habituation-dishabituation test on naive untreated mice was observed a significant reduction 
of social interaction time for both Dys +/- and Dys -/- groups. Particularly for Dys -/- groups reduction 
was observed in the first trial of interaction with the unfamiliar female ( interation time 11.51 s, 
p=0.0028 vs DYS +/+), in the second trial ( interation time 6.67 s, p=0.025 vs DYS +/+) and in the last 
trial after introduction of a new unfamiliar female ( interation time 11.89 s, p=0.0025 vs DYS +/+), and 
for Dys +/- a significant interaction time reduction was observed in the same trials (respectively 
interation time 29.64 s, p=0.035 vs DYS +/+ , interation time 14.90 s, p=0.0036 vs DYS +/+ , interation 
time 20.70 s, p=0.00018 vs DYS +/+)( Figure 5). 
Same test in males revealed no significant difference between the 3 groups (Figure 6) 
 
 
Figure 5 Dys female mice show reduced social interaction between unfamiliar females. Data depict the 
amount of time in seconds allocated to investigation of the same unfamiliar female during each of four 
successive 1-min trials. A fifth `dishabituation' trial depicts the response of the subject females to the 
presentation of a new unfamiliar female in a 1-min pairing 3 min after the fourth trial. Ns= 13 Dys+/+, 15 Dys+/-
, 3 Dys-/-.  
(*) p<0.05, (**) p<0.005 and (***) p<0.0005 vs. respective trial of DYS+/+. 
Values represent mean ± SEM throughout all Figures. 
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Figure 6 Dys male mice don’t showreduced social interaction between unfamiliar males. Data depict the amount of 
time in seconds allocated to investigation of the same unfamiliar male during each of four successive 1-min trials. A fifth 
`dishabituation' trial depicts the response of the subject females to the presentation of a new unfamiliar female in a 1-min 
pairing 3 min after the fourth trial. Ns= 16 Dys+/+, 13 Dys+/-, 4 Dys-/-. No significant difference was observed 
Values represent mean ± SEM throughout all Figures. 
 
2.3.4 Social deficits in female-female interaction in Dys mutant mice are ameliorated by acute 
intranasal oxytocin 
 
As oxytocin has extensively involved in the modulation of social-related behaviors (Bielsky & Young, 
2004; Mariaelvina Sala et al., 2011b, 2013; Winslow & Insel, 2002). Thus, in order to assess possible 
rescue effects of chronic intranasal oxytocin treatment in the social deficits that has been found both 
in Dys +/- and Dys -/- mutant mice, we tested mice acutely and chronically treated with intranasal 
oxytocin or vehicle in the social habituation-dishabituation test (Huang et al., 2014).  
In female-female social habituation –dishabituation test, acute administration of oxytocin 
ameliorated social deficit observed in both Dys+/- and Dys -/-. Particularly for Dys -/- was observed a 
significant increase of social interaction time vs control for trial 1 (p=0.004), 2 (p=0.002), 5 (p=0.0003), 
while for dys-/- was observed a significant improvement of sociability for trial 1 (p=0.02); while for 
trial 5 there was still a trend of improvement (p=0.08). No effect was observed in Dys-/- group treated 
with oxytocin. 
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Figure 7 Acute intranasal OXT treatment reverted decrease in social interaction between unfamiliar females. 
Data depict the amount of time in seconds allocated to investigation of the same unfamiliar female during each 
of four successive 1-min trials. A fifth `dishabituation' trial depicts the response of the subject females to the 
presentation of a new unfamiliar female in a 1-min pairing 3 min after the fourth trial. Ns= 11 Dys+/+ VEH, 14 
Dys+/- VEH, 5 Dys-/- VEH, 12 Dys+/+ OXT 0.3 IU/5 µl, 12 Dys+/- OXT 0.3 IU/5 µl, 7 Dys-/- OXT 0.3 IU/5 µl.  
(*) p<0.05, (**) p<0.005 , (***) p<0.0005 OXT 0.3 IU/5 µl vs VEH. 
Values represent mean ± SEM throughout all Figures. 
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After chronic treatment was not observed anymore any significant difference in interaction times . 
 
 
 
 
Figure 8 Chronic intranasal OXT treatment in social interaction between unfamiliar females. Data depict the amount of 
time in seconds allocated to investigation of the same unfamiliar female during each of four successive 1-min trials. A fifth 
`dishabituation' trial depicts the response of the subject females to the presentation of a new unfamiliar female in a 1-min 
pairing 3 min after the fourth trial. Ns= 11 Dys+/+ VEH, 14 Dys+/- VEH, 5 Dys-/- VEH, 12 Dys+/+ OXT 0.3 IU/5 µl, 12 Dys+/- 
OXT 0.3 IU/5 µl, 7 Dys-/- OXT 0.3 IU/5 µl.  
Values represent mean ± SEM throughout all Figures. 
 
2.3.5 Chronic intranasal oxytocin ameliorates social deficits in familiar mice 
 
Unfamiliar Dys mutant males do not show deficits of sociability VS same sex stimulus mice, as 
observed in social habituation-dishabituation test Figure 6. This is probably becouse the meeting 
between unfamiliar males involves different aspects from the commonly-defined meaning of 
“sociability”. In fact in this context, an intruder-response might be involved that we cannot distinguish 
from common sociability. Moreover, as observed in  social habituation-dishabituation test, we could 
highlight easily a treatment-induced decrease in sociability, while stress of manipulation for intranasal 
chronic treatment could increase social interaction covering possible deficits. This effect was observed 
also in literature too in a 3 chamber paradigm (K L Bales et al., 2014). For these reasons, we decided 
to study effects of chronic treatment in  familiar males that should possibly be less stressed and prone 
to a “normal” sociability between individuals.  In this context we observed  a significant decrease in 
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duration of events of total social behaviours VS  vehicle WT both for vehicle Dys +/- (p<0.05) and for  
vehicle Dys -/-  (p<0.0005). Moreover, we observed an increase in non social behaviour in Dys(-/-) 
(p<0.05). For all these groups, deficit was ameliorated after administration of chronic intranasal 
oxytocin, as  all mutant treated individuals (both Dys +/- than -/-) do not significantly differ from WT 
Vehicle group.. 
 
 
Figure 9 Chronic intranasal OXT treatment reverted decrease in male-male social behaviours in Dys heterozygous 
knockout mice. (A) Duration of events of total social behaviours. (B) Duration of events of  total non-social behaviours. Ns= 
14 Dys+/+ VEH, 12 Dys+/- VEH, 7 Dys-/- VEH, 10 Dys+/- OXT 0.15 IU/5 µl, 7 Dys-/- OXT 0.15 IU /5 µl, 12 Dys+/- OXT 0.3 
IU/5 µl, 8 Dys-/- OXT 0.3 IU/5 µl. (*) p<0.05, (**) p<0.005, (***) p<0.0005 vs. Dys+/+ VEH group. 
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2.3.6 Oxytocin doesn’t reduce receptor expression in dys mutant mice 
 
Matching behavioral findings, we are finding that, conversely to wild-type mice (Huang et al., 2014), 
intranasal OXT did not affect or even rescued the constitutive decrease of OXTR in selective brain 
areas of dysbindin-1 knockouts (some preliminary in Figure 10). 
 
 
Figure 10 Quantification of OXT-receptor (OXT-R) binding in various brain areas. OXT-R ligand binding in Dysbindin-1 
mouse forebrain. Quantitation of the autoradiographic 20 pmol/l I
125
-labeled OXT-R antagonist was obtained using NIH 
ImageJ- Software. Data is expressed as nCi/mg tissue equivalent (1 way and 2-way ANOVAs. N = 5 for WT groups, N = 4 for 
all Dys groups. (+), (*) p < 0.05; (**) p < 0.01 vs WT VEH. (^) p < 0.05 vs Dys+/- VEH. (A) Lateral Septum media region; (B) 
Nucleus Accumbens; (C) Amygdala; (D) Prefrontal cortex. 
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2.4 Discussion 
  
Our experiments have confirmed that the Dys knockout mutant mice show reduced social interaction 
both in the male-female interaction test and in the female-female social habituation dishabituation 
test. This phenotype has been suggested as rodents' correlate of negative symptoms (social 
withdrawal) in schizophrenia and was observed in literature in different social paradigms (Feng et al., 
2008; Hattori et al., 2008). The demonstration of social deficits in 2 different paradigms indicates that 
dysbindin 1 mutant mice are a good model for the study of negative symptoms associated to 
schizophrenia. Thus, the Dys mouse model presents an invaluable tool in the investigation of the 
aetiology of schizophrenia and in the search and test of novel and more effective therapies for 
schizophrenia-associated social deficits. With social deficits in mind for which as yet there are no 
effective therapies concerning human schizophrenia, we tested whether acute or chronic intranasal 
administration of oxytocin (OXT), a neuropeptide that has been shown to mediate various social 
behaviours (Lim et al., 2005; Mariaelvina Sala et al., 2011a; Winslow & Insel, 2002), with promising 
initial results in patients, could ameliorate these deficits. The encouraging results from our male-
female interaction test, in chronically treated Dys mutant mice, and in female- female social 
habituation-dishabituation in acutely treated Dys mutant mice, provides evidence that both chronic 
and acute intranasal OXT could rescue the social deficits exhibited by these mice. Curiously, chronic 
administration in females did not lead to a significant variation of cognitive performance from treated 
vs untreated mutant mice but just a trend of improvement. However , watching accurately the data is 
possible to observe a general increase of sociability in both treated and untreated group after one 
week of chronic administration that suggests certaineffects of stress derived from prolonged handling 
for daily intranasal administration that raises the baseline sociability of the saline control mice 
masking any possible drug improvement effect. The same effect was observed by Bales (K L Bales et 
al., 2014) after a chronic protocol of intranasal administrations, though in a different social paradigm 
(the tree chamber test). This statement suggests that, within the context of an intranasal admiration 
protocol, social habituation-dishabituation test can probably highlight only detrimental effects as a 
consequence of the treatment (Huang et al., 2014) while it could be unreliable for possible positive 
effects. 
This leads us to the question of how OXT goes about mediating these social behavioural effects. It is 
not clear whether OXT is exerting its prosocial effects by influencing relatively broad states and 
orientations (e.g., general anxiety, affiliative motivation, global saliency of social cues) or by 
interacting with specialised higher-order social cognitive processes (e.g., trust, generosity, 
suspiciousness, mentalising) (Churchland and Winkielman, 2012). 
According to molecular results (autoradiography) is noticeably observable that DYS mutant mice 
chronically administered with intranasal oxytocin do not show a downregulation in oxytocin receptor 
expression. That result correlates with our results where, in fact, improvement of social performance 
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is observed just in mutant mice and with behavioural results  already observed (Huang et al., 2014)  
on C57BL/6j where a chronic administration of intranasal oxytocin in males showed a detrimental 
effect  in males. Noticeably in this study chronic administration in females did not show the decrease 
of sociability previously observed in the same test in males suggesting some sex differences in 
oxytocin action in male and in female. This data is coherent with different roles of oxytocin in males 
and in females and with literature  that observed different oxytocin and oxytocin receptor expression 
in males and females in pre-natal period (Tamborski, Mintz, & Caldwell, 2016), and sex specific 
behavioural effects in adult mice (Steinman et al., 2015).  
Finally, involvement of dysbindin-1 reduction seems to trigger some molecular mechanism that 
conditions responsivity to oxytocin. Indeed while pro-social effects were really effective  both in acute 
and in chronic in our female and male DYS mutant mice, in wild type either no effect or a detrimental 
effect was observed (Huang et al., 2014) while other groups in different model of social withdrawal 
both genetic (K L Bales et al., 2014) or stress induced (Steinman et al., 2015) failed to rescue the 
phenotype. This oxytocin intranasal treatment has a great therapeutic potential for social deficits 
triggered by specific causes as dysbindin reduction, and probably other that still need to be explored. 
This molecule should be collocated in a paradigm of personalized-therapy, and the limits of 
applicability of this therapy may take advantage of the mouse models relevant for psychiatric disease. 
Moreover, its inefficacy or detrimental effects in unaltered system prevents the abuse of this 
molecule in a recreational context.  
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Abstract 
 
CRF is a 41 amino acid neuropeptide involved in the stress response. In patients with Alzheimer’s 
disease, a greater cognitive impairment was associated with lower CRF concentrations in the CSF. 
Moreover, preliminary evidence suggests that ICV administration of CRF might improve cognitive 
functions in rats. This might suggest a potential use of CRF as a cognitive enhancer. This positive 
effect, however, could be prevented by the remarkable anxiogenic effects driven by the CRF. 
To overcome these limitations, a possible strategy could be to avoid the alteration of CRF levels in 
brain areas responsible for the anxiogenous-related effects.CRF brain levels are regulated by the CRF 
binding protein (CRFbp), which shows a region-specific pattern of expression. CRFbp is expressed in 
the cortex and hippocampus of both humans and rodents. Interestingly, rats administrated ICV with 
the CRF(6-33), a peptide inhibiting CRF and CRFbp binding, showed improved cognitive 
functions  without exhibiting anxiogenic effects.  
To demonstrate the effectiveness of CRF(6-33) by intranasal administration we first tested C57BL/J 
naïve mice in a modified five Choice Serial Reaction Time Task (5-CSRTT) paradigm. Our results show 
selective behavioral effects after intransal administration of CRF(6-33),  particularly a reduction of 
impulsive behaviour. We also found that  while acute administration produces some cognitive 
improvements, chronic administration might be detrimental. Furthermore, intransal CRF BP was able 
to change the expression of key players of the CRF-system such as CRF1 receptor in hippocampus and 
CRFbp in  PFC. 
Finally, we tested the effects of intransal CRFBP in  genetically modified mice relevant to 
schizophrenia. We selected mice mutated for dysbindin-1 an D2L as they are two leading 
susceptibility genes in schizophrenia both involved in dopamine signalling and we had initial evidence  
that these genetic mutations   might increase  impulsive behaviours. We confirmed that these mice 
have an increased impulsive behaviour. However acute administration of CRF(6-33) was not able to 
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rescue it. Moreover, these preliminary data are  showing an interesting  trend of exacerbation of the 
impulsive phenotype in Dys +/- mice suggesting a negative interaction of CRF(6-33) with the 
genotype. 
These results indicate that intransal CRF(6-33) is able to modulate  impulsive beahaviours and that 
these effects might change depending on the genetic background. 
3.1 Introduction 
 
3.1.1 Cognitive deficits in schizophrenia  
 
Cognitive deficits are a core and enduring feature of schizophrenia. These deficits are relatively stable 
over time across changes in clinical state (Harvey & Bowie, 2003; Nielsen, 2011; Sharma & Antonova, 
2003), tend to persist throughout the course of the illness (Heaton et al., 2001) and have high 
correlation with the functional outcome of patients (Sharma and Antonova, 2003; Carter et al., 2008; 
Green et al., 2004). Cognitive impairments are wide-spread and severe, affecting various cognitive 
domains of speed of processing, attention/ vigilance, working memory, verbal learning, visual 
learning, reasoning, problem solving and social cognition (Keith H Nuechterlein et al., 2008). Among 
these affected domains, abnormalities in attention have been considered to be fundamental because 
the lack of selection of relevant information may be a cause of impairment in the other domains (Gold 
& Thaker, 2002; Zvyagintsev, Parisi, Chechko, Nikolaev, & Mathiak, 2013). Broadly speaking, attention 
is the ability to select a subset of the available information for preferential processing, while ignoring 
competing information (Smid, Martens, de Witte, & Bruggeman, 2013). There are different forms of 
attentional processes that can be measured with different tasks. In general, tasks in which attention is 
directed to the same stimulus on all stimulus presentations (i.e. on the basis of instructions) engage 
sustained selective attention, while tasks in which attention is directed to different stimuli on 
different stimulus presentations (i.e. on the basis of pre-cues and sometimes referred to as 'transient 
attention') enlist selective attention switching (Smid, de Witte, Homminga, & van den Bosch, 2006; 
Smid et al., 2013). Sustaining and switching of attention can operate in the visual-spatial and the 
object domain of selection (Smid et al., 2013). For example, if during a number of sequential stimulus 
presentations in a task, one is required to focus one's attention always on the same location in the 
visual field while ignoring other stimulated locations, the task is a sustained attention task in the 
visual-spatial domain (Smid et al., 2013). On the other hand, if between stimulus presentations in a 
task, one's focus of attention has to be switched from one location to another (on the basis of cues), it 
is a spatial attention switching task (Smid et al., 2013). Mounting evidence suggests that patients with 
schizophrenia have an intact implementation of attention (i.e. sustained attention) while being 
impaired in the control of selection (i.e. switching the focus of attention) (Smid et al., 2013) and broad 
monitoring (Hahn et al., 2012).  
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3.1.2 CRF system as a pharmacological target for cognitive modulation 
Corticotropin Releasing Factor (CRF) is a 41 amino acid neuropeptide involved in stress responses 
(Mitchell, 1998). 
Involvement of this molecule in cognitive functions was initially studied in patients affected by 
Alzheimer’s desease where a greater cognitive impairment was associated with lower CRF 
concentrations in CSF (De Souza, Whitehouse, Kuhar, Price, & Vale, 1986; Pomara et al., 1989). 
Moreover this peptide has been strongly investigated as a neuromodulator able to improve cognitive 
functions in rodent models by ICV administrations (Behan et al., 1995; Eckart et al., 1999; S C 
Heinrichs et al., 1997; Stephen C Heinrichs & Koob, 2004; Stephen C. Heinrichs & Joppa, 2001; 
Stephen C. Heinrichs, 2003; Koob & Bloom, 1985; Lee et al., 1993; Lee & Sung, 1989; Thompson et al., 
2004) 
These evidences might suggest a potential use of CRF as a cognitive enhancer. However, this would be 
prevented by its remarkable anxiogenic effects (Arborelius, Owens, Plotsky, & Nemeroff, 1999; Behan 
et al., 1995; Contarino, Heinrichs, & Gold, 1999; Mitchell, 1998; Takahashi, 2001). 
To overcome these limitations, a possible strategy could be to avoid the manipulation of CRF levels in 
brain areas responsible for the anxiogenous-related effects.  
In this context, our attention moved to another molecule belonging to the CRF system, CRF binding 
protein (CRFbp). CRFbp regulates CRF brain levels acting as a sponge for CRF and limiting the quantity 
of free CRF (Jahn et al., 2005). This protein shows a region-specific pattern of expression and is 
specifically expressed in the cortex and hippocampus of both humans and rodents (Timofeeva, 
Deshaies, Picard, & Richard, 1999).  
To target this protein we decided to use the synthetic peptide CRF(6-33), being it a subpart of the 
original CRF molecule that keeps the ability to bind CRFbp with same strength of CRF, but which lost 
its ability to bind CRF receptors (Sutton et al., 1995). Administration of this molecule aims in fact to 
dissociate part of CRF from its binding protein, thus increasing the free CRF available just in the areas 
of brain where CRFbp is expressed. 
Interestingly, rats administrated ICV with CRF(6-33) showed improved cognitive functions, without 
showing anxiogenic effects (Stephen C. Heinrichs & Joppa, 2001). 
The initial interest for CRF(6-33) was focused on the development of possible treatments for cognitive 
impairments associated with Alzheimer’s disease (Behan et al., 1995). However, the combination of 
administration route (ICV) and presence of neurodegeneration in CRFergic neurons (Bissette, 
Reynolds, Kilts, Widerlöv, & Nemeroff, 1985) makes this kind of therapeutic  strategy not suitable for 
the treatment of Alzheimer’s disease. 
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Nevertheless, there are many psychiatric diseases that are associated with cognitive impairment, 
included schizophrenia (O’Carroll, 2000), where this impairment is not concomitant with 
neurodegeneration.  
The aim of this study is to test the potential of CRF(6-33) intranasal administration as a treatment for 
cognitive deficits associated with psychiatric disorders. In a clinically-relevant perspective, we aimed 
at investigating whether the intranasal route of administration could be an effective way to apply 
these drugs. To try to achieve this purpose, we firstly tested the activity of CRF(6-33) in C57BL/6j mice 
that are a classical standard genetic background strain for genetically-modified mice and animal 
models in neuroscience. Secondly we tested this intranasal CRF(6-33) in a genetically-modified mouse 
model relevant for schizophrenia.  
The test used for assessing cognitive performance is a modified version of the 5-choice serial reaction 
time task. This test allowed us to perform many manipulations and to asses different aspects of 
cognitive performance.  
3.1.3 5-Choice serial reaction time task, a test for assessment of cognitive performance in rodents  
In the clinic, the Continuous Performance Test (CPT), a visual vigilance task, has been used extensively 
as a measure of sustained/selective attention deficits in schizophrenic patients (Cornblatt, Risch, Faris, 
Friedman, & Erlenmeyer-Kimling, 1988; Gold & Thaker, 2002; Keith H Nuechterlein & Dawson, 1984). 
Briefly, in CPT tasks, subjects are presented with series of stimuli (e.g. letters or auditory tones) and 
are required to respond only to an infrequent target stimulus (typically 10 to 20% of the total stimulus  
presentations) over a period of 3 - 10 minutes. Hence, subjects are required to sustain an attentive 
state over a period of time. During this period, subjects are monitoring for a single target letter (e.g. 
C) or a target sequence of letters (e.g. A, B, C) while variants of this task may present other types of 
targets (Gold & Thaker, 2002; K H Nuechterlein & Dawson, 1984). The visuospatial selective attention 
domain has been studied extensively in schizophrenic patients. The Spatial Attentional Resource 
Allocation Task (SARAT) has been described and validated as a tool for manipulating the size of the 
attentional focus in space (Hahn, Ross, & Stein, 2006). Briefly, participants were required to keep their 
eyes fixated on a central circle containing a fixation cross and to detect a target signal (500 ms) that 
could occur at any of four peripheral locations marked by empty circles (Figure 11) Cues were 
displayed in the central circle for a variable stimulus-onset-asynchrony (SOA) of 400, 700, 1000 or 
1300 ms prior to target onset and remained on display until 500 ms after target termination. These 
cues consisted of quarters of the fixation circle turning black with their location, indicating the 
probable location of the peripheral target. One, two, three or four quarters could turn black 
simultaneously. Hence, predictability of the target location is varied across trials. Targets consisted of 
a peripheral circle filling with a checkerboard of grey and white squares of 3x3 pixels each. Upon 
occurrence of a target, subjects were instructed to press a button with their right index finger as 
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quickly as possible. The temporal unpredictability of targets required subjects to continuously allocate 
attention to cued locations in anticipation of a target.(Hahn et al., 2012, 2006). 
 
 SARAT 
 
Figure 11 Components of a single target trial in the SARAT. Onset of a central cue preceded target onset by a variable 
SOA of 400, 700, 1000 or 1300 ms. The target was presented for 500 ms in the continuing presence of the cue, which 
remained on display until 500 ms after target offset. Only screen background was then presented for an inter-trial interval (iti) 
that varied in length such that total trial duration was always 2700 ms. No-target trials differed only in that no target occurred. 
One, two, three or all four target locations could be cued at the same time, thus varying the predictability of the target. [From 
(Hahn et al., 2006).]  
 
The 5-CSRTT has been used for measuring effects of drugs and other manipulations on various aspects 
of attentional control over performance in rodents. The primary outputs measured in this test are:  
correct responses, accuracy, premature responses, perseverative responses and correct response 
latencies (Robbins, 2002). It has been widely used in studies of cognitive disruption with relevance to 
numerous clinical disorders such as attention deficit/hyperactivity disorder (ADHD) (Barbelivien, 
Ruotsalainen, & Sirviö, 2001; Davies et al., 2009; Navarra et al., 2008), Alzheimer's disease (Balducci, 
Nurra, Pietropoli, Samanin, & Carli, 2003; Lehmann, Grottick, Cassel, & Higgins, 2003), Parkinson's 
disease (Walitza et al., 2007), schizophrenia (Amitai & Markou, 2009; Amitai, Semenova, & Markou, 
2007; Carli, Calcagno, Mainini, Arnt, & Invernizzi, 2011; Carli, Calcagno, Mainolfi, Mainini, & Invernizzi, 
2011; Le Pen, Grottick, Higgins, & Moreau, 2003; Murphy, Dalley, & Robbins, 2005; Paine & Carlezon, 
2009), among others. This task has been previously described by Robbins and coworkers (Robbins, 
2002). Succinctly, the 5-CSRTT is implemented in a specially designed operant chamber with multiple 
target locations on a front wall allowing the measurement of possible nose-poke responses through 
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the use of infra-red beams placed inside the nose-poke targets. Food pellets were presented as food 
reinforcements delivered from a magazine at the rear of the chamber. 
 
Figure 12 The five-choice serial reaction time task (5-CSRTT). Top: Representation of apparatus consisting of: a 
chamber with a rear magazine equipped with a pellet dispenser and a mechanism for detecting head entries (nose-pokes) 
into that magazine, an array of five equally spaced holes, each equipped with a light bulb and an infrared nose-poke detector 
on 1 wall in the front of the chamber. Bottom: possible trial sequences in the task. Subjects initiate trials by responding to the 
rear magazine; after an inter-trial delay (iti), a brief stimulus is presented in one of the five holes. Subjects must respond to 
that hole (correct response) within a certain time to be rewarded with a food reinforcement. If they respond to the wrong hole 
(incorrect response), respond before the stimulus is presented (premature response), or fail to respond (omission), they are 
subjected to a time-out (house-light turned off) before the next trial begins. [Modified from (Nithianantharajah et al., 2012).]  
 
Some advantages of using the 5-CSRTT task include a low within- and between group subjects 
variance and although the performance generally reaches high levels (e.g. >80% accuracy; >80% 
correct responses), this is not at ceiling and it is still  possible theoretically to detect improvements 
(Robbins, 2002). Moreover, the stable baselines of performance obtained with the 5-CSRTT have 
made it a useful test for the repeated assessment of effects of systemically administered drugs in 
groups of well-trained rodents, especially as performance often returns to baseline quite rapidly 
(Robbins, 2002). Another important advantage of the 5-CSRTT is that it is capable of measuring 
several different types of performance that include aspects of attention, impulse control, processing 
speed, and cognitive flexibility (Amitai & Markou, 2011; Robbins, 2002). This is done by devising 
different test procedures and configuring the test chamber in different ways which can increase the 
versatility of 5-CSRTT by selectively enhancing the cognitive load on different aspects of the task 
(Amitai & Markou, 2011; Robbins, 2002). In spite of the many advantages, there are a few limitations 
to this task. For example, this test usually requires long training periods and food restriction before 
starting the training. Imposed food-restriction has been found to introduce additional stress to 
animals (Ilott et al., 2014). Therefore, we set out to implement a modified training protocol that run 
three sessions during the night (when the mice are more active) on the 5-CSRTT apparatus that would 
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speed up the training process as compared to conventional 5-CSRTT protocols that run only 1 session 
a day with food restriction. Moreover, our new protocol does not require the mice to be food 
restricted before starting the training, as once they have learnt the task, they are able to eat enough 
during the training/test sessions to be maintained at equal to or more than their baseline weight. This 
has the advantage of decreasing the amount of stress on the mice through removal of the need to 
perform food restriction. Through communication with the TestDiet company (Tes), it has been 
assured that the food reward pellets (5TUL Purified rodent tablet, TestDiet) are a complete diet for 
rodents. For these reasons, we have chosen to use the 5-CSRTT as one of the cognitive tests in our lab 
to evaluate cognitive function in mice that are genetically modified for schizophrenia susceptibility 
genes. 
3.1.4 Disbindin 1 and Dopaminer D2 receptor interaction as a mouse model relevant to 
schizophrenia   
Dysbindin-1 (Dys) and the dopamine D2 receptor (D2) genes are two important candidate risk genes 
for schizophrenia. In particular, they are both involved in the regulation of dopamine signalling which 
is centrally implicated in the pathophysiology and treatment of schizophrenia. It has been established, 
in fact, that genetic mutations reducing Dys expression lead to an up-regulation of D2 receptors on 
the neuronal cell surface, thus, producing a D2-hyperdopaminergic functional state and a pattern of 
abnormal excitability in PFC circuits (Iizuka et al., 2007; Papaleo & Weinberger, 2011; Papaleo, Yang, 
et al., 2012). In schizophrenia, a decreased D1/D2 activation ratio due to excessive D2 signalling may 
induce alterations of cortical network excitability, leading to abnormal representation of external and 
internal stimuli and hence, to psychiatric symptoms and cognitive disabilities (Winterer & 
Weinberger, 2004). The D2 gene produces two different isoforms: the long (D2L) and the short form 
(D2S). These two isoforms differentially contribute to dopamine signalling in the PFC and striatum 
(Usiello et al., 2000). Moreover, in humans, polymorphisms in the D2 gene have been reported to 
affect its splicing, resulting in an altered expression of D2L versus D2S (Zhang et al., 2007). Notably, 
recent results indicate that these functional genetic variants in the D2 gene are differently expressed 
in patients with schizophrenia (Kaalund et al., 2013) and might modulate schizophrenia-related 
phenotypes by modifying D2S/D2L ratio (Bertolino et al., 2009).  
In light of these results, our hypothesis is that synergistic effects of a reduced dys expression and an 
increased D2S/D2L ratio in the same subject might cause an excessive alteration in the dopamine/D2 
signalling able to trigger cognitive deficits and psychotic symptoms. Using genetically-modified mice 
for D2L and dysbindin-1, a combined approach is employed to dissect the behavioral and functional 
alterations relevant to schizophrenia in these mouse models. Emphasis has been placed on cognitive 
deficits as these are core enduring symptoms in schizophrenia which dramatically contribute to poor 
functional outcomes in patients (Papaleo, Lipska, et al., 2012; Young, Powell, Risbrough, Marston, & 
Geyer, 2009).  
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Another main aim of this project was to assess the potential efficacy of CRF(6-33) in reverting 
cognitive deficits observed after DYS-D2L reduction in mice. We performed these tests with the 
CRF(6-33) in the 5-CSRTT manipulations SARAT and Impulsivity test. 
 
3.2 Materials and Methods 
 
3.2.1 Subjects 
 
All procedures were approved by the Italian Ministry of Health (permit n. 230/2009-B) and strictly 
adhere to the recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health in U.S.. C57BL/6J male mice between 12 to 20 weeks of age used in this 
study were obtained from Charles River Laboratories (France). Animals were housed two to four per 
cage, in a climate-controlled animal facility (22 °C ± 2 °C) and maintained on a 12-hour light/dark 
cycle, with food and water available ad libitum throughout the experiments. All behavioral testing and 
procedures were conducted during the light phase of the cycle. The experimenter handled the mice 
on alternate days during the week preceding the first behavioral test. Experimenters were blind to the 
mouse genotypes and treatments during testing and behavioral scoring.  
 
3.2.2 Intranasal CRF(6-33) administration 
 
CRF(6-33) (Tocris Bioscience, Bristol, UK) was dissolved in distilled water and administered intranasally 
in a volume of 5µl to each mouse in dose of 20µg/5 µl (4mg/ml), 10µg/5 µl (2mg/ml) and 2,5µg/5 µl 
(0.5mg/ml) that corresponded respectively to ≈6.21 x10-09,≈3.10 x10-09 and≈7.76 x10-10 mol CRF(6-33), 
for each administration of 5 µl (CRF(6-33) 20µg ≈ 526 µg/kg, CRF(6-33) 10µg ≈ 263 µg/kg, CRF(6-33) 
2,5µg ≈ 65,8 µg/kg ). The dose of 10µg/5 µl was initially chosen in order to be one of the highest 
possible as there was no literature data on intranasal bioavailability of CRF(6-33). Tocris datasheet 
guaranteed 1mg/ml solubility that was also higher than the concentration used in literature by ICV 
administration (S C Heinrichs et al., 2001; Stephen C. Heinrichs & Joppa, 2001; Stephen C. Heinrichs, 
2003). We verified initially that the solubilization in water of CRF(6-33) 2mg/ml was possible. That 
concentration permitted, for 5µl administration (the optimal volume for adult mice (Huang et al., 
2014) ), an administration of a dose about 4 times higher  than the oneused in rats (normalized for 
body weight) and about 20 times lower than the common ICV dose used in the literature (S C 
Heinrichs et al., 2001; Stephen C. Heinrichs & Joppa, 2001; Stephen C. Heinrichs, 2003).  
A 20 µl Eppendorf pipette with gel-loading tips (Costar no. 4853) were used for administration. Drops 
of the 5 µl solution were gently placed equally on both nostrils of each mouse, and from there they 
were inhaled reflexively. Control mice received the same volume of distilled water (veh). 
Administration was rapid (less than 30 seconds) and handling was consistent across treatment groups. 
The detailed timelines of each procedural manipulation and CRF(6-33) treatments are reported in 
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Figure 13. Briefly, for the chronic intranasal treatments, mice were administered once a day at 6.15 
PM, 45 minutes before first night session of test for 21 consecutive days and tested as described 
below, one hour after the last administration. For the acute intranasal treatments, mice were 
administered only once, 45 minutes before the first session of test. The acute test was performed in a 
latin square design with 6 days of washout between each treatment and the following one. The delay 
of 45 minutes was chosen based on evidence indicating that intranasal administration of peptides has 
usual peak of concentration between 10-80 minutes, with peaks of concentrations for bigger peptides 
as insulin between 20 and 40 minutes (Born et al., 2002).For the CRF(6-33) we expected a 
pharmacokinetic much slower than for oxytocin due to the bigger molecular size and due to the 
peculiar mod of action of CRF(6-33).  The CRF(6-33), indeed, shows an indirect agonist effect due to 
displacement of the peptide from a binding protein. 
 
Figure 13 Timeline of treatment and manipulations for 5-CSRTT. 
 
3.2.3 5-CSRTT 
 
Apparatus 
Training and testing was conducted in 12 operant chambers (ENV-307A; Med Associates, St. Albans, 
VT, USA), housed in sound-attenuating boxes each containing a fan, which provided ventilation and a 
constant low background noise. 2 strings of LED lights (1 providing warm light and the other cool light) 
were installed onto the ceiling of each of the sound-attenuating box controlled by a timer so that the 
12-hour light/dark cycle can be regulated within each box. Each operant chamber contains, on 1 wall, 
5 nose-poke holes (1 cm in diameter; ENV-115C-A) that are each outfitted with a recessed LED 
stimulus light (ENV-313M). 2 additional LED cue lights (red and green) are installed above each of the 
5 nose-poke holes. Nose-pokes were detected by an infrared beam transecting the aperture of each 
hole. On the wall opposite the 5-hole array, a food magazine with an infrared beam (ENV-303M) and a 
head entry detector (ENV-303HDA) where food reinforcement in the form of a food pellet (5TUL 
Purified rodent tablet, TestDiet) was delivered by a pellet dispenser (ENV-203-14P). A water dispenser 
had been built into each operant chamber to ensure that the mice have access to water over the 
night during the training/test sessions. A house-light (ENV-315M) was located 7 cm above the food 
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magazine. The operant chambers are connected to a Smart Control Panel (SG-716B) and interfaced to 
a Windows computer equipped with a MED-PC IV software (Med Associates, St. Albans, VT, USA).  
 
 
 
Figure 14 5-CSRTT apparatus 1. Wall with 5 nose-poke holes, each outfitted with a recessed LED stimulus light and 2 
additional LED cue lights (red and green) above each of the 5 nose-poke holes. 2. Food magazine on wall opposite 5-hole 
array. 3. Food pellet dispenser. 4. Water dispenser. 5. House-light. 6. Smart Control Panel. 
  
 
Habituation 
 
Mice were handled on alternate days during the week preceding the start of 5-CSRTT training (3 
handling sessions; 1 min per mouse per session). During these handling sessions, the mice were 
weighed to obtain a baseline of their ad libitum body weight. No food restriction was imposed on the 
mice before training. After each of the handling sessions, each mouse was also presented with 10 
pellets so that they were habituated to the food reinforcement. Throughout training and the test 
variations after, mice were placed into the operant chambers in the evening between 5 - 6 pm and 
taken out of the chambers the following morning between 10 - 10:30 am every day and placed into 
regular holding cages (in cages of 4 mice). When the animals were taken out of the operant chambers 
in the morning, they were weighed to check that their body weights were maintained above 90% of 
their ad libitum body weight. No food was given to the mice during the day when they were in the 
regular holding cages. The food reward pellets are appropriate as a complete diet for the animals. 
However, if any of the mice were not doing well enough in the training sessions and were losing 
weight (<85% of their ad libitum body weight), an appropriate amount of regular food pellets were 
given to them when they were placed in their regular holding cages in the morning. 
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Training protocol 
Each night, mice were presented with 3 sessions spread out over the dark phase (8 pm - 8 am). 
The general protocol of each session is as follows: 
A free reinforcement pellet is issued at the start of each session. When a head entry to retrieve the 
free reinforcement pellet has been detected, the ﬁrst trial will begin with an inter-trial interval (ITI). 
Any nose-pokes during the ITI will be recorded as premature responses and will result in a time-out 
(default 5s) with the house-light turned on. At the end of the time-out, the house-light will be turned 
back oﬀ and the ITI will restart. Any nose-pokes during the time-out will reset the time-out. 
At the end of the ITI, the program will randomly select a stimulus location (1 out of 5 stimulus lights) 
and turn on the corresponding stimulus light. The stimulus light will remain on for the stimulus 
duration (SD) value set. The animal has the limited hold (LH) time to nose-poke into the lit hole. If the 
animal nose-pokes into the correct lit hole before the LH time runs out, this is recorded as a correct 
response, the ﬁrst response to stimulus will be recorded, the stimulus light will be turned oﬀ if not 
turned oﬀ earlier, the correct response latency will be recorded, and the pellet will be issued. The 
animal must now do a head entry to retrieve the pellet. Any nose-pokes before retrieving the reward 
will be recorded as perseverative responses. 
If the animal responds to one of the nose-poke holes that is not lit, this is recorded as an incorrect 
response, the ﬁrst response to stimulus will be recorded, the stimulus light will be turned oﬀ if not 
turned oﬀ earlier, the incorrect response latency will be recorded, and the house-light will be turned 
on for the time-out period. At the end of the time-out, the house-light will be turned back off and the 
ITI will start. Any nose-pokes during the time-out will reset the time-out. 
If the animal does not nose-poke into any hole before the limited hold time runs out, this is recorded 
as an omission error, the ﬁrst response to stimulus will be recorded as 0, the stimulus light will be 
turned oﬀ if not turned oﬀ earlier, the correct/incorrect response latency will be recorded as 0 (this 
value will not aﬀect the average correct/incorrect response latencies), and the house-light will be 
turned on for the time-out period. At the end of the time-out, the house-light will be turned back oﬀ 
and the ITI will start. Any nose-pokes during the time-out will reset the time-out. If a pellet was 
issued, then when the head entry is detected, the program will record the latency to reward and then 
start timing the ITI. Any nose-pokes during the ITI will be recorded as premature responses and will 
result in a time-out with the house-light turned on. At the end of the time-out, the house-light will be 
turned back oﬀ and the ITI will restart. Any nose-pokes during the time-out will reset the time-out. 
After the ITI ends, the next trial will start immediately. 
Training consists of 6 stages. To proceed to each subsequent stage, mice are required to reach the 
criterion for 2 consecutive sessions. Each stage is more challenging than the last, with the SD and LH 
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period decreasing while other criteria (such as the required number of correct trials) become more 
demanding. Each 30-minute session has a maximum limit of 100 trials. 
1. Stage 1: SD=20 s; LH=30 s; ITI=2 s. Criteria: ≥30 correct trials; ≥30% correct. 
2. Stage 2: SD=10 s; LH=30 s; ITI=2 s. Criteria: ≥50 correct trials; ≥ 50% correct. 
3. Stage 3: SD=8 s; LH=20 s; ITI=5 s. Criteria: ≥50 correct trials; ≥50% correct  
4. Stage 4: SD=4 s; LH=10 s; ITI=5 s. Criteria: ≥50 correct trials; ≥80% accuracy; ≤50% omission. 
5. Stage 5: SD=2 s; LH=7 s; ITI=5 s. Criteria: ≥50 correct trials; ≥80% accuracy; ≤40% omission. 
6. Stage 6: SD=1 s; LH=7 s; ITI=5 s. Criteria: ≥50 correct trials; ≥80% accuracy; ≤40% omission. 
 
The following measures were recorded to assess task performance: 
1. Percent choice accuracy: Number of correct responses divided by sum of number of correct 
and incorrect responses, multiplied by 100. 
2. Percent correct responses: Number of correct responses divided by total number of trials, 
multiplied by 100. 
3. Percent incorrect responses: Number of incorrect responses divided by total number of trials, 
multiplied by 100. 
4. Percent omissions: Number of omissions divided by total number of trials, multiplied by 100. 
5. Percent premature responses : Number of premature responses divided by sum of correct, 
incorrect, premature, perseverative and time-out responses (total number of responses), 
multiplied by 100. 
6. Percent perseverative responses : Number of perseverative responses di-vided by total 
number of responses, multiplied by 100. 
7. Number of time-out responses. 
8. Average latency to a correct response: Total time from onset of light stimulus to the 
performance of a correct response divided by number of correct responses. 
9. Average latency to collect a food reward: Total time from the performance of a correct 
response to the retrieval of the food reward from the food magazine divided by number of 
correct responses. 
 
Stabilization 
Upon reaching stage 6, mice are subjected to 1 week of testing at Stage 6 with a maximum of 100 
trials. After stable performance is achieved, mice are tested with a number of diﬀerent test protocols. 
SARAT 
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The mice are then submitted to two sessions of SARAT testing (with 3 different trial types randomly 
presented). Trial type 1 is the normal trial type as in Stage 6 where the stimulus light is turned on 
randomly in 1 of the 5 nose-poke holes. Trial type 2 is the same as trial type 1 with the addition of a 
red cue light over each stimulus light. In this trial type, the red cue light over the corresponding 
correct stimulus light is turned on from 1 s before to 1 s after the stimulus light duration. Trial type 3 
is the same as trial type 1 with the addition of a red cue light over each stimulus light. In this trial type, 
the red cue lights over all ﬁve stimulus lights are turned on from 1 s before to 1 s after the stimulus 
cue duration. Any nose-pokes after the red LED cue light is lit, but before the stimulus light is 
presented, is considered a premature response and is not rewarded but results in a time-out (even if 
it was in the correct response hole). Each trial type is presented equally in a random fashion 
throughout each session 
For chronic test experiments mice are treated since the first day of SARAT manipulation test, then 
chronically every day at 6.15 PM, 45 minutes before of the first session of testing. The mouse has to 
perform the SARAT protocol just the day 1 and the day 4 of test . Day 2,3, and 5,6 the mouse is tested 
in normal STAGE6 test.  
For acute latin square test mice are treated at 6.15 PM (45 minutes before of first session of testing) 
just the day of the test . Mice are divided in 4 groups and they receive one of the 3 doses of CRF(6-33) 
or vehicle according to scheme of Table 1a. After 6 days of washout (when mouse is tested in normal 
STAGE6) the mouse is treated as before 45 minutes before the test and receives a different dose of 
CRF(6-33). This cyle is repeated 4 times, and each time with a different dose. 
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Table 1: Figure 6: Latin square scheme of treatment (a) and experimental timeline (b) 
  
DAY1 DAY2 DAY3 DAY4 
47 
 
 
 
Figure 15 SARAT protocol for mice 
 
 
Distractor test 
This test was presented only in chronic treatment. 
Subsequently to SARAT testing after 2 days of STAGE6 protocol mice are submitted to Distractor 
testing (with 2 diﬀerent trial types randomly presented) (day 7, and day 10). In trial type 1 here the 
red cue light over the corresponding correct stimulus light is turned on from 1 s before to 1 s after the 
stimulus light duration. This trial type occurs 80% of the time. Trial type 2 occurs 20% of the time and 
is the same as trial type 1 with the addition of a green cue light over stimulus lights 1, 3, and 5. In this 
trial type, the green cue lights over the three stimulus lights are turned on ﬂashing from 1 s before to 
1 s after the stimulus cue duration. Any nose-poke occurring after the red/green LED cue lights are lit, 
Trial Type 1 
Trial Type 2 
Trial Type 3 
A stimulus light turns on 
randomly in 1 of 5 spatial 
locations (nose-poke 
holes). 
A red LED cue light 
(randomly in 1 out of 5) 
will turn on 1 sec before 
the corresponding 
stimulus light turns on. 
All 5 red LED cue lights will 
turn on 1 sec before a 
stimulus light turns on 
randomly in 1 of the 5 
nose-poke holes. 
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but before the stimulus light is presented, is considered a premature response and is not rewarded 
but results in a time-out (even if it was in the correct response hole). Mice are tested on Stage 6 
protocol as normal on days 8, 9, and 11, 12 . 
 
 
 
 
 
 
Screening for impulsivity 
The mice are then submitted to the impulsivity test (day 13 and day 16) .Mice are tested on Stage 6 as 
normal on days 14, 15 and 17.When the Impulsivity protocol is loaded the ITI is increased from 5 sec 
to 7 sec. This requires that mice now wait an additional 2 seconds between trials before the make a 
response. The SD and LH remain unchanged. 
 
  
Trial Type1 
Trial Type2 
1 sec after the RED led cue light turns on 
(randomly in 1 out of 5), a corresponding 
stimulus light will turn on. 
A red LED cue light 
(randomly in 1 out of 5) will 
turn on 1 sec before a 
corresponding stimulus light 
turns on 
3 green lights 
(DISTRACTORS) are flashing 
on and off 1 sec before to 1 
sec after the stimulus light 
turns on 
Figure 16 Distractor protocol for mice 
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3.2.4 Molecular analyses 
 
After 17 day of chronic treatment with 5µl of 2mg/ml CRF(6-33) mice have been administrated one 
last time 45 min before sacrifice and dissection of brain. 
 
Olfactive bulbs, prefrontal cortex, striatum and hippocampus samples have been collected for each 
mouse and rapidly frozen in dry ice inside 1,5ml Eppendorf tubes, and kept in a freezer at -80°C until 
use. 
 
RNA extraction: 
 
RNA extraction was performed by GenEluiteTM Mammalian Total RNA Miniprep Kit (Sigma-Aldrich) 
using the protocol provided by the producer. Brefly. Samples have been then measured at a 
Nanodrop 1000 (Thermo scientific) spectrometer for concentration and tested for eventual phenols 
contamination (260/230 absorbance). Samples with an absorbance of 260/230 lower than 1.7 were 
considered phenol contaminated ad were precipitated again together with samples with a low 
concentration of RNA. RNA re-precipitation was performed adding 0.1 volume of 3M sodium acetate 
(ph5.2) and 2.2 volumes of ice cold ethanol 100%. After that, tubes have been kept for 20 minutes in 
freezer and centrifuged (14,000xg) for 20 minutes. Following this, the pellets of samples were washed 
with 500 µl of ice cold 70% ethanol, spinned for 5 minutes (12,000xg) and supernatant was discarded. 
The pellets have been then inverted on a towel 1 h to dry and were dissolved again in a appropriate 
volume of RNAse free water. Concentration was than verified again at the Nanodrop. 
 
Retrotranscription: 
 
All samples have been retro transcribed by High-Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems) to a final concentration of about 45ng/2µl following the protocol of the kit producer. 
 
Real time PCR  
 
For real time PCR the following taqman probes (lifetechnologies) have been used : 
 
Murine CRFr1 : Mm00432670_m1  
Murine CRFr2 : Mm00438303_m1 
Murine CRFbp : Mm01283832_m1 
HPRT (as internal reference) :  Mm00446968_m1  
 
The probes have been used together with the TaqMan® Universal Master Mix II, with UNG 
(lifetechnologies, catalog number 4440042).  
Each sample  was tested in duplicate , according to producer protocol.  Each assay used FAM 
functionalized taqman probes. Relative expression of samples treated with CRF(6-33) vs vehicle was 
tested using the 2-ΔΔCt method. 
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In this method it is defined a threshold of fluorescence, above the highest baseline value, in which 
amplification of samples is in exponential phase (linear doubling phase of amplification). According to 
this threshold definition, Ct (Threshold cycle) is the cycle number at which the fluorescence signal 
crosses threshold. That number inversely correlates with initial template concentrations. 
 
With the method of 2-ΔΔCt it is possible to evaluate the relative expression of one gene in one group of 
samples (e.g. treated group) vs the same gene in another group (control group). 
 
To calculate the 2-ΔΔCt first was calculated the ΔC of each group, defined as difference between Ct 
value of target gene and Ct value of an internal control (that is supposed to be unchanged by the 
treatment) 
 
ΔCt1 = Ct (Target A ‐treated) –Ct (Ref B-treated) 
ΔCt2 = Ct (Target A‐control) –Ct (Ref B-control) 
 
Then it is performed difference between the two CT values ΔΔCt 
 
ΔΔCt = ΔCt1 (treated) – ΔCt2 (control) 
 
2-ΔΔCt gives an estimation of how the expression of a target gene varies in the treated group VS control 
(e.g. 2-ΔΔCt = to 2 means a doubling of expression in the treated group,  2-ΔΔCt = to 0.5 means half of 
expression). 
 
Samples of PFC,hippocampus and olfactive bulbs have been tested for CRFr1, CRFr2 and CRFbp, while 
samples of striatum just for CRFr1. Results of CRFr2 from PFC and hippocampus have been discarded 
due to the low expression that leaded to a really high variability among both controls and treated 
samples. 
 
 
3.2.5 Statistical analyses 
 
Results are expressed as mean ± standard error of the mean (sem) throughout  all the experiments. 
One- or two-way analyses of variance (ANOVAs) were used for each single parameter measured. 
Newman-Keul’s post-hoc test was used for making comparisons between groups when the ANOVA 
showed statistical signiﬁcant diﬀerences for the main factors. The accepted value for signiﬁcance was 
p≤0.05. All statistical analyses were performed using the software Statistica version 11 (Statistica, 
StatSoft, Inc.). 
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3.3 Results 
 
3.3.1 CRF (6-33) improves accuracy acutely and reduces impulsive response both acutely and 
chronically 
 
To study cognitive performance and attention with the 5-CSRTT 12 C57BL/6j mice were initially 
recruited. After 21 days of training 3 mice have been excluded from the test due to their unreliable 
performance in poke pattern. 
The remaining 9 mice received 7 additional days with normal training protocol (stage 6). In 
accordance to their performance of last 3 days of stabilization mice have been assigned to 2 balanced 
groups: 5 mice were assigned to treatment group, 4 to control group. As shown in Figure 17 
performance of two groups were comparable and there were no significant differences. In pictures is 
reported only accuracy and premature respones data in order to give a reference to following results, 
other parameters have been evaluated but none resulted significantly different in the two groups. 
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Figure 17 Performance of treatment and control group last 3 days of stabilization. None of the group has still received 
any treatment. Performance of the two groups are substantially similar.  
Treatment Group N=5, control group N=4 
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3.3.2 During SARAT manipulation CRF(6-33) improves accuracy and reduces impulsive responses  
 
 
The first manipulation tested was the SARAT test. On the first day of intranasal administration mice 
showed a significant improvement of accuracy (p= 0.00014), ascribable to an acute effect of 
administration. This effect in fact disappear after 4 days of chronic treatment.  
 
Figure 18 Increased accuracy of response after acute administration of CRF(6-33) during SARAT manipulation. The 
CRF(6-33) treated group (N=5) had a significant (*** P<0.0005) improvement of performance the first day of treatment VS the 
control group (N=4) 
 
 
Figure 19 Reduction of premature responses after acute administration of CRF(6-33) during SARAT manipulation. 
The CRF(6-33) treated group (n=5) had a significant reduction of premature responses vs the control group (n=4) that is 
maintained after 4 days of treatment  
 *** P<0.0005 , * P<0.05  
Interestingly in this test was observed  a significant reduction in premature responses both the first 
day of treatment (p= 0.00018) and after 4 days of chronic treatment (p=0.0014). 
Time out responses are significantly reduced in CRF(6-33) group only for acute administration. All the 
other parameters evaluated during this manipulation are unchanged in the 2 groups, confirming that 
the alterations that we see are specific for some cognitive features.  
*** 
Day 4 CRF(6-33) 
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Figure 20 Timeout responses and % of perseverative responses:reduction of timeout responses after acute 
administration of CRF(6-33) during SARAT manipulation (** P<0.005). Reduction of timeout responses was observed only 
acutely and disappeared the 4th day of administration. Ns: VEH=4, CRF(6-33) =5   
  
** 
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Figure 21 latency to reward collection and latency to correct response are unaffected during the first 4 days of 
treatment CRF(6-33): n=5; Control group: n=4 
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3.3.3 During DISTRACTOR manipulation CRF(6-33)still reduces impulsive responses 
 
On the 7th day of chronic administration mice received their first session of DISTRACTOR manipulation 
test.  
In this test is commonly evaluated the effect on accuracy during trial type 2 (DISTRACTOR test).  
 
 
 
 
 
      
Figure 22 Accuracy and Premature responses performance during distractor manipulation. Premature responses after 
4 days of intranasal treatment with CRF(6-33) are still significantly reduced (*p<0.05). No more effects on accuracy are 
visible.  
Values represent mean ± SEM throughout all Figures. 
 
In this context accuracy was not modified by the treatment. Interestingly instead prematures 
responses are still significantly reduced (p≤0.05 ) during trial type 1 (red led cued trial in the context 
of this manipulation). This trial is analogus to the trial type 2 of SARAT manipulation where this kind of 
effect was observed, suggesting an effect on impulsivity mantained after 7 days of chronic 
administration. This effect disappeard the day 10 in concomitance with the 2nd presentation of 
DISTRACTOR protocol test, suggesting an adaptative mechanism to chronic administration of CRF(6-
33).  
 
 
Day 4 CRF(6-33) 
* 
Day 7 CRF(6-33) 
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Figure 23 Perseverative % and timeout responses during distractor manipulation.  
CRF(6-33): N=5; Control group: N=4 Values represent mean ± SEM throughout all Figures. 
 
 
 
 
 
 
  
Day 4 CRF(6-33) Day 7 CRF(6-33) 
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Figure 24 Latency to reward collection and latency to correct response are unaffected during DISTRACTOR 
manipulation after 7 days of treatment: CRF(6-33): n=5; Control group: n=4 
Day 4 CRF(6-33) Day 7 CRF(6-33) 
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3.3.4 IMPULSIVITY manipulation results: 
 
During the impulsivity manipulation the relevant parameter evaluated (premature responses) was 
unchanged in the two groups. 
Interestingly on latencies times was observed an unexpected effect: both latency to correct response 
(p<0.05) and latency to reward retrieval (trend) were increased in treated groups. 
 
 
Figure 25: Latencies are increased by CRF(6-33) after 2 weeks of chronic administration . 
Latency to correct response was significantly increased (*p<0.05) for for CRF(6-33) groups control. Latency to reward 
collection shows a trend of increase . 
CRF(6-33): n=5; Control group: n=4 
 
3.3.5 Real time PCR analysis confirms the ability of intranasal CRF(6-33) to modify expression of 
key molecules for the CRF system. 
 
From real time PCR analisis we observed a significant increase of CRFbp expression of 23% (p<0.05) 
selectively in PFC (Figure 26 a). No effect of CRF(6-33) was observed in Hippocampus. Regarding to 
CRFr1 we observed a 25% significant (p<0.05) decrease of receptor selectively in Hippocampus (Figure 
26 d). We tested also olfactive bulbs for CRFr1, CRFr2 and CRFbp, but none of them was 
significantively modified in this samples (Figure 27). 
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Figure 26 CRF(6-33) induces a significant relative mRNA increase of expression for CRFbp in PFC (*p<0.05) and a 
significant decrease of expression of CRF1 in Hippocampus.(*p<0.05) in Real Time PCR analysis.  
 
  
* 
* 
a b 
d c 
e 
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Figure 27 CRF(6-33) doesn’t affect a significantly relative mRNA expression for CRF1, CRF2 and CRFbp of olfactive 
bulbs in Real Time analysis. 
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3.3.6 Acute lower dose of CRF(6-33) is still able to reduce impulsive behaviour 
 
We tested acutely CRF(6-33) in SARAT manipulation using a Latin square paradigm in the 5-CSRTT. 
Treatment have been performed just the day of SARAT manipulation test, while the following days 
mice had to perform just the normal stage6  training test without additional administrations for 6 
days of washout.  
As in previous paradigm we observed a significant reduction (**P<0.01 ) of prematures responses for 
the lowest dose  
 
 
 
 
 
 
 
 
 
 
 
Surprisingly that effect was observed only for the lowest dose and not for the higher. Following that 
observation we hypothesized a probable residual effect of previous treatments. Probably the mice 
were not completely recovered from the washout period (6 days). To eventual relevable effect we 
checked performance of mice during stage6.We checked mice performance during the day following 
the administration and we observed a dose dependent increase of premature responses for the 2 
highest dose groups evidencing a relevant residual effect the day after administration ( 2mg/ml 
p<0.05, 4mg/ml p<0.01 ) suggesting a rebound effect .  
** 
Figure 28 0.5mg/ml CRF(6-33) administration rduces significantly % of premature responses in a latin square 
protocol 5-CSRTT  
(**p<0.01) (N=12) 
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Figure 29 Preamature responses the day following administration in the latin square protocol; CRF(6-33) groups 
show a significant increase of premature responses (*P<0.05, **p<0.01) 
3.3.7 Administration of acute intranasal CRF(6-33) may interact in opposite way with 
schizophrenia relevant mutations Dys+/- and D2L+/-  
We tested acutely CRF(6-33) in the IMPULSIVITY  manipulation of 5-CSRTT to test specifically effects 
on impulsivity responses that was the most promising effect observed so far for this drug. We chose 
to use the double mutant mouse model for genes Dys and D2L. They were chosen for a specific 
impulsivity deficit associated to double mutant mouse. Moreover we tested the single mutants to 
observe effects of interaction  of CRF(6-33) with each single mutation. 
Mice have been trained to the criteria as described in 3.2.3 for 5-choice protocol. Then they have 
been tested once for IMPULSIVITY without any treatment.  
After 7 days they received intranasal administration of CRF(6-33) 45 minutes before the test. 
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Figure 30 Dys +/- , D2L +/- show a significant impulsive behaviour (p<0.05) 
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Figure 31 Effect of CRF(6-33) on schizophrenia relevant mice during IMPULSIVITY manipulation in Dys +/+ D2L +/+, 
Dys +/+ . D2L +/-, Dys +/- D2L +/+, Dys +/- D2L +/-. None of the groups has shown significant differences VS control. Wild 
type show a trend of improvement (p=0.08 in T-Test) and Dys+/- show a trend of worsening of the phenotype( p=0.07 In T-
Test) 
 
None of the group has shown a significant change of performance after CRF(6-33) administration. 
However, these results have to be considered preliminary data due to the low number of subjects in 
CRF(6-33) treated groups. It is discernible a trend of improvement in WT group, that is in accordance 
with previously observed data on WT and a trend of worsening of phenotype in Dys +/- D2L+/+ group 
that, if confirmed might indicate a negative interaction with Dys deficiency. 
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3.4 Discussion 
 
In men, CRF was proven to be an important molecule for cognition. This has been confirmed in studies 
of Alzheimer’s patients (De Souza et al., 1986; Pomara et al., 1989) and in rodent studies in which CRF 
was administered via ICV (Behan et al., 1995; Eckart et al., 1999; S C Heinrichs et al., 1997; Stephen C 
Heinrichs & Koob, 2004; Stephen C. Heinrichs & Joppa, 2001; Stephen C. Heinrichs, 2003; Koob & 
Bloom, 1985; Lee et al., 1993; Lee & Sung, 1989; Thompson et al., 2004). In an experimental, pre-
clinical context in which there was acute ICV administration of CRF(6-33), CRF was proven to be 
effective in eliciting  pro-cognitive effects on spatial memory (Behan et al., 1995). This was achieved 
without causing the undesired anxiogenic effects of the CRF itself that had been observed in rodents 
(Behan et al., 1995). In humans in phisiopathological conditions leading to a contextual increase in 
CRF was observed an increase of the state of anxiety   (Mitchell, 1998; Takahashi, 2001) and in 
stressful conditions, such as the withdrawal from abused drugs and personal stress, which can cause 
hyperstimulation of the CRF system.  
Since ICV administration of CRF is not suitable for human psychiatric therapy, our first aim was to 
determine whether it was possible to use this molecule by intranasal administration. Our second aim 
was to determine the proper therapeutic dose and assess any chronic effects of its use. 
To assess cognitive performance, we chose to use a modified version of 5-CSRTT that was previously 
validated in our lab (data not yet published) with the advantage of reducing  the training period from 
39-day–to-several month sessions to 10-to-30-day sessions, which eventually resulted in a real 
operational session of 14 to 21 days (de Bruin, Fransen, Duytschaever, Grantham, & Megens, 2006; 
Papaleo, Erickson, Liu, Chen, & Weinberger, 2012; Patel, Stolerman, Asherson, & Sluyter, 2006). 
Additionally, our modification of the 5-CSRTT paradigm included the introduction of two new kinds of 
manipulations, i.e., 1) SARAT, primarily designed to assess broad monitoring abilities and 2) distractor 
manipulation, which permits us to assess the ability of patients to focus their attention in the 
presence of distractive events. This modification was introduced because both of these abilities are 
impaired in schizophrenic patients. The third kind of manipulation, the impulsivity test, was used 
specifically to assess impulsivity, which also is altered in schizophrenic patients. 
Initially, we chose to test the drug in a dose of 5µl with a concentration of 2mg/ml. This was about 20 
times higher? the minimal effective dose tested in rats via ICV (normalized by weight). This dosage 
was chosen to provide the highest chance of achieving an effective therapeutic concentration in the 
brain. The first battery of tests was performed in C57BL/6j mice, because this strain of mice is the 
strain that is most extensively used for genetic and behavioural studies. First, acute administration 
did, in fact, increase the accuracy in SARAT manipulation significantly, and it decreased impulsivity. 
After acute intranasal administration of CRF(6-33), the results were comparable to the results that 
were observed using ICV administration in rats (Behan et al., 1995). However, after sub-chronic 
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administration, this initial effect became unstable, but the effect on impulsivity was maintained much 
longer, i.e., for as long as seven days of sub-chronic administration.  Moreover, the progression of the 
chronic administration of the drug did not lead to any additional cognitive improvement, but it 
increased the latency times required for the treated mice to respond and collect the reward.  
These data indicated that the most promising and constant effect of the intranasal administration of 
CRF(6-33) was on impulsive behavior. The data indicated that prolonged treatment, i.e., more than a 
week, may lead to the worsening of general performance.  
Our initial observations allowed us to answer the first question, i.e., CRF(6-33) can be delivered in 
active doses by intranasal administration. To confirm this observation that was made in the 
behavioural test, we performed molecular tests of real time PCR on dissected areas of the mice brain. 
In this experiment, we observed that animals treated with CRF(6-33) had a significant decrease in the 
expression of CRF1 receptors in the hippocampus and increased expression of CRFbp in PFC. These 
effects, together with the behavioural effects, clearly confirmed the ability of CRF(6-33) to reach the 
brain intranasally and partially explained the decrease in the response to the local increase of CRF. 
Interestingly, in different parts of the brain, the compensatory responses that were observed were 
quite different, i.e., PFC increased the binding protein, which likely would result in the reduction of 
free CRF, but in the hippocampus, they led to a reduction of CRF1 receptor expression, which likely 
reduced the responsivity of the neurons to the CRF. These two compensatory effects probably have a 
different timing profile, which likely resulted in the different time of compensation observed in the 
behavioural performance. This should be confirmed by additional temporal-specific molecular studies. 
Thes results, also suggest the possibility of interfereing with one (or both) of these molecular 
adaptation mechanisms to obtain either a more specific or a more prolonged effect.  
Secondly, based on our initial results, we decided to assess CRF(6-33) as an acute treatment and to 
define a proper therapeutic dose for the following studies. Thus, we performed a 5-CSRTT in the 
SARAT manipulation, which already has been shown to be sensitive to pharmacological manipulation 
in the first pilot test, in an acute latin square design. In this design, we tested all the groups for all 
available doses. We tested doses of 5 µl of the vehicle,  CRF(6-33) solutions with concentrations of 
0.5, 2, and 4 mg/ml. In this latin square paradigm, we were able to replicate the reduction of 
impulsive responses for the lowest dose that was administered. Curiously, a lack of response was 
observed for other doses, raising the prospect that, even after acute administration, there would 
likely be some residual compensatory effects that were not completely reinstated after one week of 
washout. That did not affect the lowest dose group since, according to the treatment schedule, every 
time a subgroup received the lowest dose the week after it had received the vehicle. This  led to an 
effective 13-day washout period instead of six days, as was the case in the other groups.  So, we 
observed premature response performances among the different treatment groups the day after 
treatment. For the highest dose groups, we observed a rebound effect of the premature responses 
the day after the administration, which was indicative of an increase in impulsivity. In addition, we 
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observed that the lowest dose still was able to evocate the reduction of premature responses, but it 
did not seem to evocate the rebound response that was observed for the other two groups. For the 
effectiveness and apparent safety of this dose, we used the dose of 0.5 mg/ml for the subsequent 
studies in mouse models for schizophrenia. 
The third step was to test the effect of CRF(6-33) administration in schizophrenia-relevant mice 
models. The ideal candidate for the test had to be a schizophrenia-relevant model characterized by an 
increased level of impulsivity as the main observed effect for CRF(6-33) in C57BL/6j was a reduction of 
impulsive behaviour. We chose to test Dys/D2l double heterozygous mice that, in previous tests in 
our lab, had shown increased impulsive behaviour. We also tested single Dys heterozygous and D2L 
hetero mice that seemed to have both a trend of increased impulsivity and also to check the effects of 
the administration of CRF(6-33) on the single mutations. It was possible to replicate the genotype 
deficit on the double heterozygous Dys/D2L mice. For this purpose, we performed pharmacological 
manipulation in the paradigm of the impulsivity test because it was designed specifically to assess 
impulsive behaviour.  
After performing the administrations of CRF(6-33), the preliminary data seemed to suggest a 
decreasing trend in impulsive behaviour in the WT and in the D2L group. However, there was no 
effect in the Dys/D2L double heterozygote model, and there was an increase in impulsive behaviour in 
the Dys het group. If this is confirmed by an increase of the number of samples of the groups, these 
results suggest a detrimental interaction between the pharmacological manipulation of CRF(6-33) and 
the Dysbindin mutation. To confirm these results, an increase in the populations is required, but this 
result would give additional incentive for the genetic characterization of the different forms of 
schizophrenia and of the molecular mechanism that underlies the observed phenotypes. Concerning 
similar treatments, we can expect diametrically opposed results due to the interaction with the 
genotype, and it would be desirable, advantageous, and beneficial to know how the interactions with 
genotypes after pharmacological manipulation will modify the outcome of treatments 
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Chapter 4 
 
Conclusion and Future Directions 
 
4.1 Conclusion  
Since the intranasal route of administration was demonstrated to be an option (Born et al., 2002) to 
deliver drugs to the brain, exciting new frontiers to pharmacological research have been opened. 
Indeed, intransal administrations can be used to bypass different restrictions of other route, mostly 
linked to the Blood Brain Barrier: elevated lipophilicity, small molecular weight (below 400- to 600-
Da), low number of Hydrogen bonding donors or acceptors , low polar surface area (60–70 Å  
generally, maximum limit is 90 Å ), reduced number of rotatable bonds and low flexibility, pKa 
between 4 and 10 (Pajouhesh & Lenz, 2005).  
In particular, these requisites previously precluded the use of peptide molecules as they are of  high 
molecular weight, high Hydrogen bonding, high polar surface, flexible molecules. Importantly, these  
very versatile and largely unexplored molecules embed a numerous potentiality  to influence brain 
functions (Tsomaia, 2015). 
Being able to deliver this molecules to CNS, bypassing BBB, in a non-invasive might open new 
perspectives for neurological and psychiatric disease therapy. There are plenty of natural peptides 
such as, OXT, VPS, insulin (Salameh et al., 2015) that have central effects and can be potentially used 
for therapy. Moreover, some of them (e.g. OXT and insulin) have important and undesired  periferical 
effects if injected systemically. Intransal route of administration will avoid also this issue. 
Furthermore,  instead of natural peptides, we can engineer peptides (Sato, Viswanathan, Kent, & 
Wood, 2006) to obtain different effects from natural molecules, e.g. ligand specificity (Sutton et al., 
1995), when originator natural peptide has multiple ligands or different intrinsic activity (i.e. 
antagonist activity from an agonist peptide) Or  some properties of natural peptides can be  obtained 
in a more straight-forward way (Tsomaia, 2015). 
In this thesis work we explored 2 representative and different examples taking advantage of the 
intranasal ways. On one side OXT, a natural peptide with central social-related effects On the other 
hand CRF(6-33) an engineered peptide, table-bench designed for a specific action on a target in the 
brain that was previously studied only by ICV administrations  (Behan et al., 1995; Eckart et al., 1999; 
S C Heinrichs et al., 1997; Stephen C Heinrichs & Koob, 2004; Stephen C. Heinrichs & Joppa, 2001; 
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Stephen C. Heinrichs, 2003; Koob & Bloom, 1985; Lee, Lee, Wang, & Lin, 1993; Lee & Sung, 1989; 
Thompson, Erickson, Schulkin, & Rosen, 2004). 
The overall goal  was to study, through the intranasal administration of neuropeptides, therapeutical 
strategies targeting two of the main and still untreatable alterations relevant to schizophrenia, that is, 
social and cognitive deficits (Arguello & Gogos, 2006; Kvajo, McKellar, & Gogos, 2012). 
We demonstrated that OXT intranasal administrations can reliably modulate the oxytocinergic system 
to selectively modulate social behaviour. Specifically, chronic intranasal OXT was able to ameliorate 
the social deficits found in dys +/- mice, as demonstrated by both males social interaction vs opposite 
sex and  female-female interactions Thus, Dysbindin-1 genetics could be used in the future to predict 
the behavioral resposnes to  intranasal Oxytocin.  
OXT seems to  be effective only for treatments of social deficits, but not for cognitive 
impairment(even if more studies should selectively check this). Thus, for cognitive functions we 
focused more on  the CRF(6-33), as revious literature had shown that it might ameliorate cognitive 
deficits  by ICV administrations in mice.  
CRF(6-33) our first concern was if it was possible to reach active concentration into the brain. Indeed,  
due to its mechanism of action, it needs to reach reatively high concentration to excert an effect. In 
fact, it implies to dissociate CRF from its binding protein while Ki between CRFbp-CRF-is comparable 
to Ki of CRFbp-CRF(6-33) (Sutton et al., 1995) 
Stemming from literature data on rats (S C Heinrichs et al., 1997; Stephen C. Heinrichs & Joppa, 2001; 
Stephen C. Heinrichs, 2003), we expected that active ICV dose for a mouse should range from 0.5 to 
2.5 µg  . And in a 5 µl volume we were limited initially to maximum 10 µg for administration. 
Nevertheless, we obtained an improvement of accuracy since the first experiment on C57BL/6j ,and a 
reduction of impulsivity suggesting we succeeded in obtaining a penetration of an active dose of 
CRF(6-33). A further support came from the molecular observations from real time PCR on CRF1 
receptor and CRFbp. Importantly,  the strongest and  most stable effect was found on impulsivity 
 
Thus,  we demonstrated that intranasal CRF(6-33) can reach the brain and can modulate some 
cognitive parameters relevant for schizophrenia, as accuracy and premature responses. However, our 
findings warn that these  improvements might rapidly disappears or even have some rebound effects. 
A plausible interpretation of these results is that these are probably negative feedback mechanisms to 
reduce CRF activity in response to local increase of CRF. Particularly, even if the triggering condition 
for that response is the displacement of CRF from CRFbp, the response observed is really different in 
different brain areas: in PFC there is augmented sequestration of free CRF by an increase of CRFbp 
expression while in hippocampus responsiveness to CRF it is decreased itself by the reduction of 
available receptors. 
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These mechanisms should be confirmed by other molecular data and will require furnter 
investigations. A possible  hypothesis is that downregulation of hippocampal receptors is the fast 
event and is responsible for the rapid loss of improvement on accuracy during SARAT manipulation 
(that was observed after just 4 days of administration) while increase in CRFbp expression is probably 
the slower event as putuative responsible for the loss of improvement on premature responses.  
Based on these evidence in wild type mice, because in previous studies (data unpublished) we found 
that our schizophrenia relevant mouse model double heterozygous Dys +/- D2L +/-(receptor for 
dopamine Long form) was impulsive, we tested their impulsive behaviour after acute administration 
of CRF(6-33).  
In this context, preliminary results seem to suggest no effects on impulsivity on the genotype D2L+/-
Dys+/- mice while both WT controls and D2L +/- showed a tendency to reduction of premature 
responses and Dys +/-  were found to have a higher percentage of premature responses, compared 
with littermates vehicle treated controls. Preliminary results of acute intranasal CRF(6-33) treatment 
in these mice show that it decreased the impulsivity trait both in D2L+/- and in WT, while interactions 
of pharmacological manipulation with Dys +/- genotype lead to a worsening of the impulsive trait. In 
the double heterozygote mouse model, the effect of pharmacological manipulation on the genotype 
seems to be a sum of positive effects on D2L +/- and negative effects on Dys +/- with a resultant sum 
of opposite effects almost inexistent.  
In the light of this, the best way of using CRF(6-33) and the proper target should still be better 
explored. Our preliminary studies on schizophrenia relevant mouse models highlight that this 
molecule can interact in different way with different genetic backgrounds this might be important in 
the context of developing personalized healthcare based on the genetic background of each subject.  
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4.2 Future Directions  
While current results on the effects of intranasal OXT have been encouraging. there is still 
considerable uncertainty as to the route of action and distribution of OXT following intranasal 
delivery. It is not clear whether behavioural effects that follow peripheral (olfactory route or 
trigeminal system) administration of OXT are driven by increased central concentrations of OXT due 
to the OXT entering the CNS, or to an indirect peripheral effect driving central production and release 
of OXT, or that peripheral effects of OXT may drive indirect behavioural effects through unknown 
mechanisms (Evans, Dal Monte, Noble, & Averbeck, 2014). Further studies will be needed to 
determine the route and distribution of OXT following intranasal delivery. A possible experiment to 
clarify this, could be one where, in conjunction with intranasal OXT administration, to apply a 
peripheral OXT antagonist that does not cross the blood brain barrier which would then eliminate any 
peripheral actions (by blocking peripheral OXT receptors) that might confound interpretation of 
central effects of OXT (Evans et al., 2014).  
On top of that, as the pharmacokinetics of OXT are still not fully understood, therefore, an accurate, 
specific, and readily available method for measuring OXT that can be adopted as the standard in the 
field is urgently required for progress in our understanding of OXT's roles in behaviour and cognition 
(McCullough et al., 2013).  
For CRF(6-33) instead ability of the peptide to reach its sites of action in the brain seems much less 
prone to misinterpretations. CRF(6-33) is itself a synthetic peptide designed to have no other 
interaction than with CRFbp (Sutton et al., 1995), it has no significant bind affinity for any of CRF 
receptors (Sutton et al., 1995) and molecular result cannot be explained without brain penetration. 
While we can know almost exactly where the peptide can act and that his effect is mediated by a local 
CRF agonism still it is not completely understood the underlying mechanism that induces the pro 
cognitive phenotypes observed in C57BL/6j mice and interaction with different genotypes. Further 
studies will be needed to determine the kinetic of distribution in the brain tissue and of brain 
adaptation to CRF system stimulation.  
The understanding of the interactions between multiple schizophrenia risk genes will aid in the 
development of new and more efficient ad personam therapeutic strategies to ameliorate negative 
symptoms and cognitive dysfunction in schizophrenia.  
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